Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 10-13 January 2022

Chair: Sabine Straus – Vice-Chair: Martin Huber

10 January 2022, 10:30 – 19:30, via teleconference
11 January 2022, 08:30 – 19:30, via teleconference
12 January 2022, 08:30 – 19:30, via teleconference
13 January 2022, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)
27 January 2022, 09:00 – 12:00, via teleconference

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1).
Table of contents

1. Introduction 13
   1.1. Welcome and declarations of interest of members, alternates and experts …… 13
   1.2. Agenda of the meeting on 10-13 January 2022 ……………………………………… 13
   1.3. Minutes of the previous meeting on 29 November - 02 December 2021 …… 13

2. EU referral procedures for safety reasons: urgent EU procedures 13
   2.1. Newly triggered procedures ……………………………………………………… 13
   2.2. Ongoing procedures ……………………………………………………………… 13
   2.3. Procedures for finalisation ……………………………………………………… 13

3. EU referral procedures for safety reasons: other EU referral procedures 13
   3.1. Newly triggered procedures ……………………………………………………… 13
   3.1.1. Terlipressin (NAP) - EMEA/H/A31/1514 ………………………………………… 13
   3.2. Ongoing procedures ……………………………………………………………… 14
   3.3. Procedures for finalisation ……………………………………………………… 14
   3.4. Re-examination procedures …………………………………………………… 14
   3.5. Others ………………………………………………………………………….. 14

4. Signals assessment and prioritisation 14
   4.1. New signals detected from EU spontaneous reporting systems ………………. 14
   4.1.2. Osimertinib – TAGRISSO (CAP) ……………………………………………….. 15
   4.1.3. Roxadustat – EVRENZO (CAP) ………………………………………………… 15
   4.2. New signals detected from other sources ……………………………………….. 15
   4.2.1. Human normal immunoglobulin – FLEBOGAMMA DIF (CAP), KIOVIG (CAP), PRIVIGEN (CAP); NAP …………………………………………………………… 15
   4.3. Signals follow-up and prioritisation …………………………………………….. 15
   4.3.1. Durvalumab – IMFINZI (CAP) - EMEA/H/C/004771/SDA/009 ……………. 15
   4.3.2. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/SDA/052 …………………………………………. 16
   4.3.3. Pregabalin – LYRICA (CAP); NAP - EMEA/H/C/000546/SDA/055 ………… 16
   4.3.4. Tocilizumab – ROACTEMRA (CAP) - EMEA/H/C/000955/SDA/059 ……. 16
   4.4. Variation procedure(s) resulting from signal evaluation …………………….. 16
   4.4.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005671/II/0055 ………………………………… 16

5. Risk management plans (RMPs) 17
   5.1. Medicines in the pre-authorisation phase ……………………………………….. 17
5.1. Amifampridine - EMEA/H/C/005839 ................................................................. 17
5.1.2. Budesonide, micronised - EMEA/H/C/005653, Orphan .................................. 17
5.1.3. Capmatinib - EMEA/H/C/004845................................................................. 17
5.1.4. Dimethyl fumarate - EMEA/H/C/006039....................................................... 17
5.1.5. Dimethyl fumarate - EMEA/H/C/005956....................................................... 17
5.1.6. Dimethyl fumarate - EMEA/H/C/005955....................................................... 17
5.1.7. Dimethyl fumarate - EMEA/H/C/006042....................................................... 17
5.1.8. Ganaxolone - EMEA/H/C/005825, Orphan ................................................ 18
5.1.9. Insulin aspart - EMEA/H/C/005635.............................................................. 18
5.1.10. Leuprorelin - EMEA/H/C/005034.............................................................. 18
5.1.11. Mosunetuzumab - EMEA/H/C/005680, Orphan ........................................ 18
5.1.12. PF-07321332, ritonavir - EMEA/H/C/005973 ............................................. 18

5.2. Medicines in the post-authorisation phase – PRAC-led procedures .......... 18
5.2.1. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/II/0011 ............ 18
5.2.2. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0029 .... 19
5.2.3. Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0020 ......................... 19
5.2.4. Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/II/0026, Orphan .......... 19
5.2.5. Mercaptamine - CYSTADROPS (CAP) - EMEA/H/C/003769/II/0023, Orphan 20
5.2.6. Nintedanib - OFEV (CAP) - EMEA/H/C/003821/II/0046 ......................... 20
5.2.7. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/WS2185/0041; NEPARVIS (CAP) - EMEA/H/C/004343/WS2185/0039 .... 20
5.2.8. Temozolomide - TEMODAL (CAP) - EMEA/H/C/000229/II/0095 ............. 21
5.2.9. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0087 ............. 21

5.3. Medicines in the post-authorisation phase – CHMP-led procedures ...... 21
5.3.1. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/II/0038 .......... 21
5.3.2. Brigatinib - ALUNBRIG (CAP) - EMEA/H/C/004248/II/0037 ................. 21
5.3.3. Brivaracetam - BRIVIACT (CAP) - EMEA/H/C/003898/II/0032/G .......... 22
5.3.4. Caplacizumab - CABLIVI (CAP) - EMEA/H/C/004426/II/0035, Orphan .... 22
5.3.5. Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/II/0020 .......... 22
5.3.6. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/II/0053, Orphan ......... 23
5.3.7. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0069/G .... 23
5.3.8. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0073 ....... 23
5.3.9. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0027 .......... 24
5.3.10. Eptacog alfa (activated) - NOVOSEVEN (CAP) - EMEA/H/C/000074/II/0116 24
5.3.11. Etanercept - ENBREL (CAP) - EMEA/H/C/000262/II/0246 ................. 24
5.3.12. Galsulfase - NAGLAZYME (CAP) - EMEA/H/C/000640/II/0086 .............. 24
5.3.13. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/II/0006, PRIME, Orphan ... 25
6.1. Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/II/0069 .................................. 25
6.1.6. Idecabtagene vilucel - ABECMA (CAP) - EMEA/H/C/004662/II/0010, PRIME, Orphan .................. 25
6.1.7. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/WS2049/0009; VIMPAT (CAP) - EMEA/H/C/000863/WS2049/0091/G .................................. 26
6.1.8. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/II/0009, Orphan .................................. 26
6.1.9. Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/II/0051/G .................................. 26
6.1.10. Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0117 .................................. 27
6.1.11. Ponatinib - ICLUSIG (CAP) - EMEA/H/C/002695/II/0061, Orphan .................................. 27
6.1.12. Secukinumab - COSENTYX (CAP) - EMEA/H/C/003729/II/0079 .................................. 27
6.1.13. Semaglutide - OZEMPIC (CAP) - EMEA/H/C/004174/WS2141/0024; RYBELSUS (CAP) - EMEA/H/C/004953/WS2141/0018 .................................. 27
6.1.15. Tagraxofusp - ELZONRIS (CAP) - EMEA/H/C/005031/II/0009, Orphan .................................. 28
6.1.17. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/X/0012/G .................................. 29
6.1.18. Elocetocog alfa - ELOCTA (CAP) - EMEA/H/C/00010451/202106 .................................. 32

6. Periodic safety update reports (PSURs) 29

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only .................................. 29
6.1.1. Afamelanotide - SCENESSE (CAP) - PSUSA/00010314/202106 .................................. 29
6.1.2. Alpelisib - PIQRAY (CAP) - PSUSA/00010871/202105 .................................. 29
6.1.3. Angiotensin II - GIAPREZA (CAP) - PSUSA/00010785/202106 .................................. 29
6.1.4. Atidarsagene autotemcel - LIBMELDY (CAP) - PSUSA/00010899/202106 ...................... 30
6.1.5. Azacitidine - VIDAZA (CAP) - PSUSA/00000274/202105 .................................. 30
6.1.6. Berotralstat - ORLADEYO (CAP) - PSUSA/00010930/202106 .................................. 30
6.1.7. Betibeglogene autotemcel - ZYNETEGLO (CAP) - PSUSA/00010769/202105 ...................... 30
6.1.8. Binimetinib - MEKTOVI (CAP) - PSUSA/00010717/202106 .................................. 30
6.1.9. Bromfenac - YELLOX (CAP) - PSUSA/00000436/202105 .................................. 31
6.1.10. Buprenorphine - SIXMO (CAP) - PSUSA/00010778/202105 .................................. 31
6.1.11. Cannabidiol - EPIDYOLEX (CAP) - PSUSA/00010798/202106 ...................... 31
6.1.12. Cholera vaccine, oral, live - VAXCHORA (CAP) - PSUSA/00010862/202106 ...................... 31
6.1.13. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - PSUSA/00010897/202106 .................................. 31
6.1.14. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - PSUSA/00010912/202106 .................................. 32
6.1.15. Crisaborole - STAQUIS (CAP) - PSUSA/00010842/202106 .................................. 32
6.1.16. Dasatinib - SPRYCEL (CAP) - PSUSA/00000935/202106 .................................. 32
6.1.17. Delafloxacin - QUOFENIX (CAP) - PSUSA/00010822/202106 .................................. 32
6.1.18. Dengue tetravalent vaccine (live, attenuated) - DENVAXIA (CAP) - PSUSA/00010740/202106 ...................... 32
| 6.1.20. | Encorafenib - BRAFTOVI (CAP) - PSUSA/00010719/202106 ........................................... 33 |
| 6.1.21. | Entrectinib - ROZLYTREK (CAP) - PSUSA/00010874/202106 ........................................... 33 |
| 6.1.22. | Fenfluramine - FINTEPLA (CAP) - PSUSA/00010907/202106 ........................................... 33 |
| 6.1.23. | Fluticasone furoate, vilanterol - RELVAR ELLIPTA (CAP); REVINTY ELLIPTA (CAP) - PSUSA/00010099/202105 ........................................... 33 |
| 6.1.24. | Formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - TRIXEO AEROSPHERE (CAP) - PSUSA/00010908/202106 ........................................... 33 |
| 6.1.25. | Galsulfase - NAGLAZYME (CAP) - PSUSA/00001515/202105 ........................................... 34 |
| 6.1.27. | Human papillomavirus 9-valent vaccine (recombinant, adsorbed) - GARDASIL 9 (CAP) - PSUSA/00010389/202106 ........................................... 34 |
| 6.1.28. | Hydroxycarbamide - SIKLOS (CAP); XROMI (CAP) - PSUSA/00001692/202106 ................. 34 |
| 6.1.29. | Imiglucerase - CEREMY (CAP) - PSUSA/00001727/202105 ........................................... 34 |
| 6.1.30. | Incisiran - LEQVIO (CAP) - PSUSA/00010904/202106 ........................................... 34 |
| 6.1.31. | Indacaterol, mometasone furoate - ATECTURA BREEZHALER (CAP); BEMRIST BREEZHALER (CAP) - PSUSA/00010850/202105 ........................................... 35 |
| 6.1.32. | Interferon beta-1a - AVONEX (CAP) - PSUSA/00010725/202105 ........................................... 35 |
| 6.1.33. | Interferon beta-1a - REBIF (CAP) - PSUSA/00010726/202105 ........................................... 35 |
| 6.1.34. | Laronotcinib - VITRAKVI (CAP) - PSUSA/00010799/202105 ........................................... 35 |
| 6.1.35. | Latanoprost, netarsudil - ROCLANDA (CAP) - PSUSA/00010905/202106 ........................................... 35 |
| 6.1.36. | Levodopa - INBRIJA (CAP) - PSUSA/00010780/202106 ........................................... 36 |
| 6.1.37. | Linagliptin - TRAJENTA (CAP); linagliptin, metformin - JENJUADUETO (CAP) - PSUSA/00010427/202105 ........................................... 36 |
| 6.1.38. | Luspaterecept - REBLOZY (CAP) - PSUSA/00010860/202106 ........................................... 36 |
| 6.1.40. | Netarsudil - RHOKIINSA (CAP) - PSUSA/00107812/202106 ........................................... 36 |
| 6.1.41. | Nevirapine - VIRAMUNE (CAP) - PSUSA/00002147/202105 ........................................... 36 |
| 6.1.42. | Nonacog beta pegol - REFIXIA (CAP) - PSUSA/00010608/202105 ........................................... 37 |
| 6.1.43. | Nusinersen - SPINRAZA (CAP) - PSUSA/00010595/202105 ........................................... 37 |
| 6.1.44. | Obeticholic acid - OCALIVA (CAP) - PSUSA/00010555/202105 ........................................... 37 |
| 6.1.45. | Onasemnogene abeparvovec - ZOLGENSMA (CAP) - PSUSA/00010848/202105 ................. 37 |
| 6.1.46. | Opicapone - ONGENTYS (CAP) - PSUSA/00010516/202106 ........................................... 37 |
| 6.1.47. | Palivizumab - SYNAGIS (CAP) - PSUSA/00002267/202106 ........................................... 38 |
| 6.1.48. | Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - ADJUPANRIX (CAP) - PSUSA/00002281/202105 ........................................... 38 |
| 6.1.49. | Pegvaliase - PALYNZIQ (CAP) - PSUSA/00010761/202105 ........................................... 38 |
| 6.1.50. | Pentosan polysulfate sodium - ELMIRON (CAP) - PSUSA/00010614/202106 ................. 38 |
| 6.1.51. | Pertuzumab - PERJETA (CAP) - PSUSA/00010125/202106 ........................................... 38 |
| 6.1.52. | Pertuzumab, trastuzumab - PHESGO (CAP) - PSUSA/00010906/202106 ........................................... 38 |
| 6.1.53. | Polatuzumab vedotin - POLIVY (CAP) - PSUSA/00010817/202106 ........................................... 39 |
| 6.1.54. | Propranolol - HEMANGIOL (CAP) - PSUSA/00010250/202104 ........................................... 39 |
6.3.1. **Ravulizumab** - ULTOMIRIS (CAP) - PSUSA/00010787/202106

6.3.2. **Rilpivirine** - EDURANT (CAP) - PSUSA/00009282/202105

6.3.3. **Semaglutide** - OZEMPIC (CAP); RYBELSUS (CAP) - PSUSA/00010671/202105

6.3.4. **Sildenafil** - TREVIP (-) - PSUSA/00010389/202105

6.3.5. **Loperamide** (NAP); loperamide, simeticone (NAP)

6.3.6. **Levonorgestrel** (NAP)

6.3.7. **Levofloxacin, dexamethasone** (NAP)

6.3.8. **Lanreotide** (NAP)

6.3.9. **Lactulose** (NAP)

6.3.10. **Human hemin** (NAP)

6.3.11. **Goserelin** (NAP)

6.3.12. **Flunarizine** (NAP)

6.3.13. **Daunorubicin** (NAP)

6.3.14. **Clevidipine** (NAP)

6.3.15. **Cidofovir** (NAP)

6.3.16. **Bismuth subcitrate potassium, metronidazole, tetracycline** (NAP)

6.3.17. **Amino acid combinations, glucose, triglyceride combinations, with or without electrolytes, mineral compounds** (NAP)

6.3.18. **5 fluorouracil, salicylic acid** (NAP)

6.3.19. **Imatinib** - GLIVEC (CAP); NAP - PSUSA/00001725/202105

6.3.20. **Measles, mumps, rubella vaccines (live, attenuated)** - M-M-RVAXPRO (CAP); NAP - PSUSA/0001937/202105

6.3.21. **Trexprostinil** - TREPULMIX (CAP); NAP - PSUSA/00010782/202106

6.3.22. **Turoctocog alfa pegol** - ESPEROCT (CAP) - PSUSA/00010782/202106

6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

6.2.1. **Capsaicin** - QUTENZA (CAP); NAP - PSUSA/0000533/202105

6.2.2. **Imatinib** - GLIVEC (CAP); NAP - PSUSA/00001725/202105

6.2.3. **Measles, mumps, rubella vaccines (live, attenuated)** - M-M-RVAXPRO (CAP); NAP - PSUSA/0001937/202105

6.2.4. **Trexprostinil** - TREPULMIX (CAP); NAP - PSUSA/00003013/202105

6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

6.3.1. **5 fluorouracil, salicylic acid** (NAP) - PSUSA/00000008/202105

6.3.2. **Acipimox** (NAP) - PSUSA/0000050/202105

6.3.3. **Amino acid combinations, glucose, triglyceride combinations, with or without electrolytes, mineral compounds** (NAP) - PSUSA/00010566/202106

6.3.4. **Amino acid combinations, glucose, with or without electrolytes, mineral compounds** (NAP) - PSUSA/00010566/202106

6.3.5. **Benazepril, hydrochlorothiazide** (NAP) - PSUSA/00000314/202105

6.3.6. **Bismuth subcitrate potassium, metronidazole, tetracycline** (NAP) - PSUSA/00010199/202105

6.3.7. **Cidofovir** (NAP) - PSUSA/0001055/202106

6.3.8. **Clevidipine** (NAP) - PSUSA/00010288/202105

6.3.9. **Daunorubicin** (NAP) - PSUSA/00000936/202106

6.3.10. **Flunarizine** (NAP) - PSUSA/00001416/202105

6.3.11. **Goserelin** (NAP) - PSUSA/0001562/202105

6.3.12. **Human hemin** (NAP) - PSUSA/0001629/202105

6.3.13. **Iodine** (131I) iobenguane (NAP) - PSUSA/00001764/202105

6.3.14. **Lactulose** (NAP) - PSUSA/0001821/202105

6.3.15. **Lanreotide** (NAP) - PSUSA/00001826/202105

6.3.16. **Levoflaxacin, dexamethasone** (NAP) - PSUSA/00010881/202106

6.3.17. **Levonorgestrel** (NAP) - PSUSA/00010828/202105

6.3.18. **Loperamide** (NAP); loperamide, simeticone (NAP) - PSUSA/00010665/202105
6.3.19. Milnacipran (NAP) - PSUSA/00002063/202104 .................................................. 45
6.3.20. Misoprostol (NAP) - PSUSA/00010291/202106 .................................................. 45
6.3.21. Misoprostol (NAP) - PSUSA/00010353/202105 .................................................. 46
6.3.22. Moxifloxacin (NAP) - PSUSA/00002094/202105 .................................................. 46
6.3.23. Nadifloxacin (NAP) - PSUSA/00002102/202105 .................................................. 46
6.3.24. Olodaterol, tiotropium (NAP) - PSUSA/00010489/202105 .................................. 46
6.3.25. Pamidronate (NAP) - PSUSA/00002269/202105 .................................................. 46
6.3.26. Paracetamol (NAP) - PSUSA/00002311/202105 .................................................. 47
6.3.27. Phenylpropanolamine (NAP) - PSUSA/00010483/202106 ................................ 47
6.3.28. Pholcodine (NAP) - PSUSA/00002396/202105 .................................................. 47
6.3.29. Ranitidine (NAP) - PSUSA/00002610/202105 .................................................... 47
6.3.30. Remifentanil (NAP) - PSUSA/00002617/202105 .................................................. 47
6.3.31. Triglyceride combinations, with or without mineral compounds, electrolytes (NAP) - PSUSA/00010648/202106 ................................................................. 47

6.4. Follow-up to PSUR/PSUSA procedures ................................................................. 48
6.4.1. Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/LEG 056 ............................. 48
6.4.2. Pregabalin - PREGABALIN PFIZER (CAP) - EMEA/H/C/003880/LEG 008 .... 48
6.4.3. Tenofovir disoproxil - VIREAD (CAP) - EMEA/H/C/000419/LEG 278 .............. 48

6.5. Variation procedure(s) resulting from PSUSA evaluation .................................... 48
6.5.1. Arsenic trioxide - TRISENOX (CAP) - EMEA/H/C/000388/II/0076 .................. 48
6.5.2. Baricitinib - OLMIANT (CAP) - EMEA/H/C/004085/II/0031 ............................. 49
6.5.3. Clofarabine - EVOLTRA (CAP) - EMEA/H/C/000613/II/0075 .......................... 49
6.5.4. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0035 ................................. 49
6.5.5. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0025 ..................... 50
6.5.6. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0080 .................... 50

6.6. Expedited summary safety reviews ................................................................. 50
6.6.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 028.7 .......................... 50

7. Post-authorisation safety studies (PASS) ......................................................... 51

7.1. Protocols of PASS imposed in the marketing authorisation(s) ....................... 51
7.1.1. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/PSA/S/0075.1 ........................ 51
7.1.2. Parathyroid hormone - NATPAR (CAP) - EMEA/H/C/PSA/S/0053.4 ............ 51
7.1.3. Selumetinib - KOSELUGO (CAP) - EMEA/H/C/PSA/S/0095.1 ........................ 51
7.1.4. Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/PSA/S/0080 .................... 51
7.1.5. Valproate (NAP) - EMEA/H/N/PSP/J/0074.4 .................................................. 52
7.1.6. Valproate (NAP) - EMEA/H/N/PSP/J/0077 .................................................... 52
7.1.7. Voretigene neparvovec - LUXTURNA (CAP) - EMEA/H/C/PSA/S/0081 ........... 52

7.2. Protocols of PASS non-imposed in the marketing authorisation(s) ............... 53
7.2.1. Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/MEA 003.1 ............................................... 53
7.2.2. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 004.2 ............................................... 53
7.2.3. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 005.2 ............................................... 53
7.2.4. Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006.2 ............................................... 53
7.2.5. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 004.4 ............................................... 54
7.2.6. Isatuximab - SARCLISA (CAP) - EMEA/H/C/004977/MEA 002.2 ............................................... 54
7.2.7. Patisiran - ONPATTRO (CAP) - EMEA/H/C/004699/MEA 003.2 ............................................... 54
7.2.8. Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/MEA 001 ............................................... 55
7.2.9. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 001.4 ............................................... 55
7.2.10. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 002.7 ............................................... 55
7.2.11. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 002.4 ............................................... 55
7.2.12. Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/MEA 002.1 ............................................... 56
7.2.13. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/MEA 003.1 ............................................... 56
7.3. Results of PASS imposed in the marketing authorisation(s) ............................................. 56
7.3.1. Hydroxyethyl starch (HES) (NAP) - EMEA/H/N/PSR/J/0031 ............................................... 56
7.4. Results of PASS non-imposed in the marketing authorisation(s) ........................................... 57
7.4.1. Apremilast - OTEZLA (CAP) - EMEA/H/C/003746/II/0039 ............................................... 57
7.4.2. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0028 ............................................... 57
7.4.3. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0231 ............................................... 57
7.4.4. Influenza vaccine surface antigen inactivated prepared in cell cultures - FLUCELVAX TETRA (CAP) - EMEA/H/C/004814/II/0023 ............................................... 57
7.4.5. Insulin glargine, lixisenatide - SULIQUA (CAP) - EMEA/H/C/004243/II/0024 ............................................... 58
7.4.6. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0034 ............................................... 58
7.4.7. Susoctocog alfa - OBIZUR (CAP) - EMEA/H/C/002792/II/0043 ............................................... 58
7.4.8. Teriflunomide - AUBAGIO (CAP) - EMEA/H/C/002514/II/0038 ............................................... 58
7.4.9. Trastuzumab - ONTRUZANT (CAP) - EMEA/H/C/004323/II/0036 ............................................... 59
7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation ........................................ 59
7.5.1. Aclidinium - BRETARIS GENUAIR (CAP) - EMEA/H/C/002706/ANX 001.10 ............................................... 59
7.5.2. Aclidinium - EKLIRA GENUAIR (CAP) - EMEA/H/C/002211/ANX 001.10 ............................................... 59
7.5.3. Aclidinium, formoterol fumarate dihydrate - BRIMICA GENUAIR (CAP) - EMEA/H/C/003969/ANX 003.7 ............................................... 60
7.5.4. Aclidinium, formoterol fumarate dihydrate - DUAKLIR GENUAIR (CAP) - EMEA/H/C/003745/ANX 003.7 ............................................... 60
7.5.5. Burosumab - CRYSVITA (CAP) - EMEA/H/C/004275/MEA 004.3 ............................................... 60
7.5.6. Cangrelor - KENGREXAL (CAP) - EMEA/H/C/003773/MEA 002.4 ............................................... 60
7.5.7. Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/MEA 002.2 ............................................... 61
7.5.8. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 005.2 ............................................... 61
8.3.9. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRAG (CAP) - EMEA/H/C/005675/MEA 006.2 ................................................................. 61
8.3.10. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRAG (CAP) - EMEA/H/C/005675/MEA 007.3 ........................................ 61
8.3.11. Coronavirus (COVID-19) mRNA vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 003.4 ........................................... 62
8.3.12. Ketoconazole - KETOCONAZOLE HRA (CAP) - EMEA/H/C/003906/ANX 002.8................. 62
8.3.13. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.3 .......................... 62
8.3.14. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.3 .......................... 62
8.3.15. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.2 ......................... 63
8.3.16. Sacubitril, valsartan - ENTRESTOP (CAP) - EMEA/H/C/004062/MEA 004.11 ............. 63
8.3.17. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 003.8................. 63
8.3.18. Ustekeinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 045.7 ......................... 63
8.6. Others .................................................................................. 64
8.6.1. Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/MEA 001.1 ........ 64
8.6.2. Fentanyl - INSTANYL (CAP) - EMEA/H/C/000959/LEG 028.4. ......................... 64
8.6.3. Insulin human - INSUMAN (CAP) - EMEA/H/C/000201/MEA 041.5 ..................... 64
8.6.4. Lopinavir, ritonavir - KALETRA (CAP) - EMEA/H/C/000368/LEG 121.4 ................. 64
8.7. New Scientific Advice ................................................................. 65
8.8. Ongoing Scientific Advice .......................................................... 65
8.9. Final Scientific Advice (Reports and Scientific Advice letters) ........................................ 65
8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 65
8.1. Annual reassessments of the marketing authorisation .......................................................... 65
8.1.1. Idebenone - RAXONE (CAP) - EMEA/H/C/003834/S/0029 (with RMP) ....................... 65
8.1.2. Metreleptin - MYALEPTA (CAP) - EMEA/H/C/004218/S/0023 (without RMP) ............ 65
8.2. Conditional renewals of the marketing authorisation .......................................................... 65
8.2.1. Andexanet alfa - ONDEXXYA (CAP) - EMEA/H/C/004108/R/0025 (without RMP) ....... 65
8.2.2. Bosutinib - BOSULIF (CAP) - EMEA/H/C/002373/R/0051 (without RMP) .................. 66
8.2.3. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/R/0052 (without RMP) ............... 66
8.2.4. Lorlatinib - LORVIQUA (CAP) - EMEA/H/C/004646/R/0019 (without RMP) ............. 66
8.2.5. Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - PANDEMIC INFLUENZA VACCINE H5N1 ASTRazeneca (CAP) - EMEA/H/C/003963/R/0047 (without RMP) ........ 66
8.2.6. Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/R/0030 (without RMP) ............... 66
8.3. Renewals of the marketing authorisation ............................................................................ 67
8.3.1. Beclometasone, formoterol, glycopyrronium bromide - TRIMBOW (CAP) - EMEA/H/C/004257/R/0025 (without RMP) .................. 67
8.3.2. Brodalumab - KYTHEUM (CAP) - EMEA/H/C/003959/R/0019 (with RMP) ................. 67
8.3.3. Carglumic acid - UCEDANE (CAP) - EMEA/H/C/004019/R/0011 (without RMP) ....... 67
8.3.4. Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/R/0026 (with RMP) .................... 67
8.3.5. Cenegermin - OXERVATE (CAP) - EMEA/H/C/004209/R/0037 (with RMP) .......................... 67
8.3.6. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/R/0034 (without RMP) .......... 67
8.3.7. Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/R/0053 (with RMP) .................... 68
8.3.8. Efavirenz, emtricitabine, tenofovir disoproxil - EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004250/R/0025 (without RMP) ................... 68
8.3.9. Etanercept - ERELZI (CAP) - EMEA/H/C/004192/R/0037 (with RMP) .......................... 68
8.3.10. Glecaprevir, pibrentasvir - MAVIRET (CAP) - EMEA/H/C/004065/R/0034 (without RMP) .. 68
8.3.11. Insulin lispro - INSULIN LISPRO SANOFI (CAP) - EMEA/H/C/004303/R/0013 (with RMP) .. 68
8.3.12. Osimertinib - TAGRISSO (CAP) - EMEA/H/C/004124/R/0044 (with RMP) ..................... 69
8.3.13. Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/R/0028 (without RMP) .................. 69
8.3.14. Ribociclib - KISQALI (CAP) - EMEA/H/C/004213/R/0034 (without RMP) ................. 69

9. Product related pharmacovigilance inspections ................................. 69
9.1. List of planned pharmacovigilance inspections ........................................ 69
9.2. Ongoing or concluded pharmacovigilance inspections .............................. 69
9.3. Others ........................................................................................................... 69

10. Other safety issues for discussion requested by the CHMP or the EMA .... 70
10.1. Safety related variations of the marketing authorisation ............................. 70
10.2. Timing and message content in relation to Member States’ safety announcements ............ 70
10.3. Other requests .............................................................................................. 70
10.4. Scientific Advice ......................................................................................... 70

11. Other safety issues for discussion requested by the Member States ............ 70
11.1. Safety related variations of the marketing authorisation ............................. 70
11.2. Other requests .............................................................................................. 70
11.2.1. Teriflunomide (pre-authorisation) - DE/H/7257/001/DC ................................. 70

12. Organisational, regulatory and methodological matters .............................. 71
12.1. Mandate and organisation of the PRAC ...................................................... 71
12.1.1. PRAC membership ................................................................................... 71
12.1.2. Vote by proxy ............................................................................................ 71
12.2. Coordination with EMA Scientific Committees or CMDh-v ..................... 71
12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups .... 71
12.4. Cooperation within the EU regulatory network .......................................... 71
12.4.1. Coronavirus (COVID-19) pandemic - update ............................................ 71
12.5. Cooperation with International Regulators .................................................. 71
12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee ................................................................. 71
12.7. PRAC work plan ......................................................................................... 71
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.7.1.</td>
<td>PRAC work plan 2022</td>
</tr>
<tr>
<td>12.8.</td>
<td>Planning and reporting</td>
</tr>
<tr>
<td>12.8.1.</td>
<td>Marketing authorisation applications (MAA) forecast for 2022 – planning update dated Q4 2021</td>
</tr>
<tr>
<td>12.8.2.</td>
<td>European Commission (EC) report on performance of pharmacovigilance tasks - third three-yearly report</td>
</tr>
<tr>
<td>12.9.</td>
<td>Pharmacovigilance audits and inspections</td>
</tr>
<tr>
<td>12.9.1.</td>
<td>Pharmacovigilance systems and their quality systems</td>
</tr>
<tr>
<td>12.9.2.</td>
<td>Pharmacovigilance inspections</td>
</tr>
<tr>
<td>12.9.3.</td>
<td>Pharmacovigilance audits</td>
</tr>
<tr>
<td>12.10.</td>
<td>Periodic safety update reports (PSURs) &amp; Union reference date (EURD) list</td>
</tr>
<tr>
<td>12.10.1.</td>
<td>Periodic safety update reports</td>
</tr>
<tr>
<td>12.10.2.</td>
<td>Granularity and Periodicity Advisory Group (GPAG)</td>
</tr>
<tr>
<td>12.10.3.</td>
<td>PSURs repository</td>
</tr>
<tr>
<td>12.10.4.</td>
<td>Union reference date list – consultation on the draft list</td>
</tr>
<tr>
<td>12.11.</td>
<td>Signal management</td>
</tr>
<tr>
<td>12.12.</td>
<td>Adverse drug reactions reporting and additional reporting</td>
</tr>
<tr>
<td>12.12.1.</td>
<td>Management and reporting of adverse reactions to medicinal products</td>
</tr>
<tr>
<td>12.12.2.</td>
<td>Additional monitoring</td>
</tr>
<tr>
<td>12.12.3.</td>
<td>List of products under additional monitoring – consultation on the draft list</td>
</tr>
<tr>
<td>12.13.</td>
<td>EudraVigilance database</td>
</tr>
<tr>
<td>12.13.1.</td>
<td>Activities related to the confirmation of full functionality</td>
</tr>
<tr>
<td>12.14.1.</td>
<td>Risk management systems</td>
</tr>
<tr>
<td>12.14.2.</td>
<td>Tools, educational materials and effectiveness measurement of risk minimisations</td>
</tr>
<tr>
<td>12.15.</td>
<td>Post-authorisation safety studies (PASS)</td>
</tr>
<tr>
<td>12.15.1.</td>
<td>Post-authorisation Safety Studies – imposed PASS</td>
</tr>
<tr>
<td>12.15.2.</td>
<td>Post-authorisation Safety Studies – non-imposed PASS</td>
</tr>
<tr>
<td>12.16.</td>
<td>Community procedures</td>
</tr>
<tr>
<td>12.16.1.</td>
<td>Referral procedures for safety reasons</td>
</tr>
<tr>
<td>12.17.</td>
<td>Renewals, conditional renewals, annual reassessments</td>
</tr>
<tr>
<td>12.18.</td>
<td>Risk communication and transparency</td>
</tr>
<tr>
<td>12.18.1.</td>
<td>Public participation in pharmacovigilance</td>
</tr>
<tr>
<td>12.18.2.</td>
<td>Safety communication</td>
</tr>
<tr>
<td>12.19.</td>
<td>Continuous pharmacovigilance</td>
</tr>
<tr>
<td>12.19.1.</td>
<td>Incident management</td>
</tr>
<tr>
<td>12.20.</td>
<td>Impact of pharmacovigilance activities</td>
</tr>
<tr>
<td>12.21.</td>
<td>Others</td>
</tr>
</tbody>
</table>
12.21.1. EMA guidance on companion diagnostics (CDx) – consultation CHMP/CAT assessment report (AR) CDx template - update ................................................................. 74


13. Any other business 75

14. Explanatory notes 76
1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 10-13 January 2022. See January 2022 PRAC minutes (to be published post February 2022 PRAC meeting).

1.2. Agenda of the meeting on 10-13 January 2022

Action: For adoption

1.3. Minutes of the previous meeting on 29 November - 02 December 2021

Action: For adoption

2. EU referral procedures for safety reasons: urgent EU procedures

2.1. Newly triggered procedures

None

2.2. Ongoing procedures

None

2.3. Procedures for finalisation

None

3. EU referral procedures for safety reasons: other EU referral procedures

3.1. Newly triggered procedures

3.1.1. Terlipressin (NAP) - EMEA/H/A31/1514

Applicant(s): various
PRAC Rapporteur: To be appointed; PRAC Co-rapporteur: To be appointed

Scope: Review of the benefit-risk balance following notification by Denmark of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of a list of questions (LoQ)

3.2. Ongoing procedures

None

3.3. Procedures for finalisation

None

3.4. Re-examination procedures¹

None

3.5. Others

None

4. Signals assessment and prioritisation²

4.1. New signals detected from EU spontaneous reporting systems


Applicant(s): Eli Lilly Nederland B.V. (Emgality), H. Lundbeck A/S (Vyepti), Novartis Europharm Limited (Aimovig), Teva GmbH (Ajovy)

PRAC Rapporteur: To be appointed

Scope: Signal of Raynaud’s phenomenon

Action: For adoption of PRAC recommendation

EPITT 19766 – New signal

Lead Member State(s): FI, NL

¹ Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
² Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required
³ Pending European Commission decision
4.1.2. **Osimertinib – TAGRISSO (CAP)**

Applicant: AstraZeneca AB  
PRAC Rapporteur: Menno van der Elst  
Scope: Signal of aplastic anaemia  
**Action:** For adoption of PRAC recommendation  
EPITT 19769 – New signal  
Lead Member State(s): NL

4.1.3. **Roxadustat – EVRENZO (CAP)**

Applicant: Astellas Pharma Europe  
PRAC Rapporteur: Marek Juracka  
Scope: Signal of central hypothyroidism  
**Action:** For adoption of PRAC recommendation  
EPITT 19757 – New signal  
Lead Member State(s): SK

4.2. **New signals detected from other sources**

4.2.1. **Human normal immunoglobulin† – FLEBOGAMMA DIF (CAP), KIOVIG (CAP), PRIVIGEN (CAP); NAP**

Applicant(s): Baxter AG (Kiovig), CSL Behring GmbH (Privigen), Instituto Grifols, S.A. (Flebogamma DIF), various  
PRAC Rapporteur: To be appointed  
Scope: Signal of thrombocytopenia  
**Action:** For adoption of PRAC recommendation  
EPITT 19764 – New signal  
Lead Member State(s): DE

4.3. **Signals follow-up and prioritisation**

4.3.1. **Durvalumab – IMFINZI (CAP) - EMEA/H/C/004771/SDA/009**

Applicant: AstraZeneca AB  
PRAC Rapporteur: David Olsen  
Scope: Signal of arthralgia

---

† For intravenous use only
**Action:** For adoption of PRAC recommendation

EPITT 19709 – Follow-up to September 2021

### 4.3.2. Coronavirus (COVID-19) mRNA\(^6\) vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/SDA/052

- **Applicant:** Moderna Biotech Spain, S.L.
- **PRAC Rapporteur:** Hans Christian Siersted
- **Scope:** Signal of capillary leak syndrome

**Action:** For adoption of PRAC recommendation

EPITT 19743 – Follow-up to November 2021

### 4.3.3. Pregabalin – LYRICA (CAP); NAP - EMEA/H/C/000546/SDA/055

- **Applicant(s):** Upjohn EESV, various
- **PRAC Rapporteur:** Liana Gross-Martirosyan
- **Scope:** Signal of toxic epidermal necrolysis

**Action:** For adoption of PRAC recommendation

EPITT 19723 – Follow-up to September 2021

### 4.3.4. Tocilizumab – R OACTEMRA (CAP) - EMEA/H/C/000955/SDA/059

- **Applicant:** Roche Registration GmbH
- **PRAC Rapporteur:** Brigitte Keller-Stanislawski
- **Scope:** Signal of sarcoidosis

**Action:** For adoption of PRAC recommendation

EPITT 18860 – Follow-up to September 2021

### 4.4. Variation procedure(s) resulting from signal evaluation

### 4.4.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/II/0055

- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Jean-Michel Dogné
- **Scope:** Update of section 4.4 of the SmPC in order to update the warning on thrombosis with thrombocytopenia syndrome (TTS) to indicate that the frequency after the second dose

---

\(^5\) Held 30 August – 02 September 2021
\(^6\) Messenger ribonucleic acid
\(^7\) Held 25-28 October 2021
\(^8\) Held 30 August – 02 September 2021
\(^9\) Held 30 August – 02 September 2021
is lower than after the first dose based on post-marketing data

**Action:** For adoption of PRAC Assessment Report

### 5. Risk management plans (RMPs)

#### 5.1. Medicines in the pre-authorisation phase

##### 5.1.1. Amifampridine - EMEA/H/C/005839

Scope: Treatment of Lambert-Eaton myasthenic syndrome

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

##### 5.1.2. Budesonide, micronised - EMEA/H/C/005653, Orphan

Applicant: Calliditas Therapeutics AB, Hybrid
Scope: Treatment of primary immunoglobulin A (IgA) nephropathy

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

##### 5.1.3. Capmatinib - EMEA/H/C/004845

Scope: Treatment of non-small cell lung cancer (NSCLC)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

##### 5.1.4. Dimethyl fumarate - EMEA/H/C/006039

Scope: Treatment of multiple sclerosis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

##### 5.1.5. Dimethyl fumarate - EMEA/H/C/005956

Scope: Treatment of multiple sclerosis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

##### 5.1.6. Dimethyl fumarate - EMEA/H/C/005955

Scope: Treatment of multiple sclerosis

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

##### 5.1.7. Dimethyl fumarate - EMEA/H/C/006042

Scope: Treatment of multiple sclerosis
Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.8. Ganaxolone - EMEA/H/C/005825, Orphan

Applicant: Marinus Pharmaceuticals Emerald Limited

Scope (accelerated assessment): Treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.9. Insulin aspart - EMEA/H/C/005635

Scope: Treatment of diabetes mellitus

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.10. Leuprorelin - EMEA/H/C/005034

Scope: Treatment of hormone dependent advanced prostate cancer

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.11. Mosunetuzumab - EMEA/H/C/005680, Orphan

Applicant: Roche Registration GmbH

Scope (accelerated assessment): Treatment of refractory follicular lymphoma (FL)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.12. PF-07321332, ritonavir - EMEA/H/C/005973

Scope: Treatment of coronavirus disease 2019 (COVID-19)

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. Medicines in the post-authorisation phase – PRAC-led procedures

5.2.1. Acalabrutinib - CALQUENCE (CAP) - EMEA/H/C/005299/II/0011

Applicant: AstraZeneca AB

PRAC Rapporteur: Željana Margan Koletić

Scope: Submission of an updated RMP (version 3) in order to add hepatotoxicity as an important potential risk to the list of safety concerns

Action: For adoption of PRAC Assessment Report
5.2.2. **Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0029**

Applicant: Janssen-Cilag International N.V.
PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP (version 2.4) in order to reclassify the important potential risk of venous thromboembolism (VTE) as an important identified risk as an outcome of post-authorisation measure MEA 32 finalised in October 2021, to add clinical trial VAC31518COV3003: a randomized, double-blind, phase 3 study to evaluate 6 dose levels of COVID-19 Vaccine Janssen (Ad26.COV2.S) administered as a two-dose schedule in healthy adults and to update study VAC18193RSV2008: a randomized, observer blind, phase 1 study to evaluate innate and proinflammatory responses of an Ad26.RSV.preF based vaccine, Ad26.COV2.S vaccine and Ad26.ZEBOV vaccine in adults aged 18 to 59 years as additional pharmacovigilance activities to further characterize the important identified risks of thrombosis with thrombocytopenia syndrome (TTS), immune thrombocytopenia (ITP), and VTE, and the important potential risk thrombocytopenia (excluding ITP and TTS) as an outcome of post-authorisation measure MEA 14.4 (fifth monthly summary safety report (MSSR)) finalised in September 2021. In addition, the MAH took the opportunity to include other minor updates in the RMP

**Action:** For adoption of PRAC Assessment Report

5.2.3. **Infliximab - ZESSLY (CAP) - EMEA/H/C/004647/II/0020**

Applicant: Sandoz GmbH
PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of an updated RMP (version 3.0) to remove the German registry Rheumatoide Arthritis: Beobachtung der Biologika-Therapie (RABBIT) registry as an additional pharmacovigilance activity in alignment with the RMP of the reference product and to remove the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) registry as an additional pharmacovigilance activity

**Action:** For adoption of PRAC Assessment Report

5.2.4. **Inotersen - TEGSEDI (CAP) - EMEA/H/C/004782/II/0026, Orphan**

Applicant: Akcea Therapeutics Ireland Limited
PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of an updated RMP (version 3.0) to remove carcinogenicity in rats as missing information and to add a targeted questionnaire as routine pharmacovigilance measure and a patient alert card as additional risk minimisation for liver transplant rejection. In addition, the RMP is updated to add ‘injection site reactions’ and ‘immunogenicity’ as risks not considered important for inclusion in the list of safety concerns (S.VII.1.1) and to update the patient alert card with additional warnings on hepatic monitoring and ocular toxicity. The MAH took the opportunity to include further minor updates to the RMP

**Action:** For adoption of PRAC Assessment Report
5.2.5. Mercaptamine - CYSTADROPS (CAP) - EMEA/H/C/003769/II/0023, Orphan

Applicant: Recordati Rare Diseases
PRAC Rapporteur: Eva Segovia
Scope: Submission of an updated RMP (version 1.4) in order to bring it in line with revision 2 of GVP module V on ‘Risk management systems’ and to remove ‘patients with other ocular co-morbidities’ and ‘patients receiving concomitant treatment with ophthalmic products containing benzalkonium chloride’ as missing information from the list of safety concerns
Action: For adoption of PRAC Assessment Report

5.2.6. Nintedanib - OFEV (CAP) - EMEA/H/C/003821/II/0046

Applicant: Boehringer Ingelheim International GmbH
PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: Submission of an updated RMP (version 11.0) in line with the outcome of the renewal procedure R/0025 finalised in May 2019 to remove the following safety concerns:
1) important identified risks: diarrhoea, liver enzyme and bilirubin elevations including drug-induced liver injury (DILI), bleeding, myocardial infarction; 2) important potential risks: venous thromboembolism, arterial thromboembolism excluding myocardial infarction, perforation, hepatic failure, treatment of pregnant women and teratogenicity, cardiac failure; 3) missing information: treatment of patients with moderate or severe hepatic impairment (Child Pugh B/C), treatment of black patients, treatment of patients with healing wounds, treatment of patients with severe renal impairment or end-stage renal disease, treatment of patients receiving full-dose therapeutic anticoagulation and treatment of breastfeeding women. In addition, the anatomical therapeutic chemical (ATC) code and post-marketing exposure are updated
Action: For adoption of PRAC Assessment Report

5.2.7. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/WS2185/0041; NEPARVIS (CAP) - EMEA/H/C/004343/WS2185/0039

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Anette Kirstine Stark
Scope: Submission of an updated RMP (version 3.0) as requested in the outcome of variation WS1830 competed in November 2020. In addition, the following changes have been introduced: 1) change to the agreed milestone for study CLCZ696B2320 (listed as a category 3 study in the RMP): a multicentre, randomized, double-blind, active-controlled study to evaluate the effects of sacubitril/valsartan (LCZ696) compared to valsartan on cognitive function as assessed by comprehensive neurocognitive battery and brain amyloid plaque deposition as assessed by positron emission tomography (PET) imaging in patients with chronic heart failure with preserved ejection fraction; 2) update the date for the submission of the final report for study CLCZ696B2320 from ‘Q1 2022’ to ‘Q1 2023’, 3) update of the presentation of important identified risks and important potential risks; 4) updated exposure and post-marketing data provided for the data lock point of PSUR#9 (31 July 2021)
**Action:** For adoption of PRAC Assessment Report

### 5.2.8. Temozolomide - TEMODAL (CAP) - EMEA/H/C/000229/II/0095

**Applicant:** Merck Sharp & Dohme B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** Submission of an updated RMP (version 6.1) to bring it in line with revision 2 of GVP module V on 'Risk management systems'. As a consequence, all safety concerns (important identified risks, important potential risks and missing information) are removed.

**Action:** For adoption of PRAC Assessment Report

### 5.2.9. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0087

**Applicant:** BioNTech Manufacturing GmbH

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Submission of an updated RMP (version 2.6) to include data from the booster/third dose, including data in patients who have undergone a solid organ transplantation, following the outcome of procedures II/0062 (third dose in immunocompromise as part of the primary vaccination) and II/0067 (booster dose) finalised in October 2021. The MAH took the opportunity to update the RMP regarding the discontinuation of enrolment in study C4591015: a phase 2/3 study to evaluate the safety, tolerability, and immunogenicity in healthy pregnant women 18 years of age and older and the final clinical study report (CSR) milestones.

**Action:** For adoption of PRAC Assessment Report

### 5.3. Medicines in the post-authorisation phase – CHMP-led procedures

#### 5.3.1. Alemtuzumab - LEMTRADA (CAP) - EMEA/H/C/003718/II/0038

**Applicant:** Sanofi Belgium

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Update of sections 4.4 and 4.8 of the SmPC to add adult onset Still’s disease (AOSD) to the list of adverse drug reactions (ADRs) with a frequency not known, based on a signal validated during a routine pharmacovigilance surveillance. The package leaflet is updated accordingly. The MAH took the opportunity to update the list of local representatives in the package leaflet. The RMP (version 9.0) is updated accordingly and reflect the removal of study OBS13436: International Lemtrada (alemtuzumab) pregnancy exposure cohort in multiple sclerosis (pregnancy registry).

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

#### 5.3.2. Brigatinib - ALUNBRIG (CAP) - EMEA/H/C/004248/II/0037

**Applicant:** Takeda Pharma A/S
PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study AP26113-13-301 (listed as a post-authorisation efficacy study (PAES) in Annex II): a randomised, open-label, multicentre phase 3 study comparing brigatinib versus crizotinib in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not previously received ALK-directed therapy. The RMP (version 5.4) is updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.3. Brivaracetam - BRIVIACT (CAP) - EMEA/H/C/003898/II/0032/G

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Adam Przybylkowski

Scope: Grouped variations consisting of: 1) extension of indication to include patients from 1 month to 4 years of age for treatment with Briviact (brivaracetam). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The RMP (version 8.0) is updated accordingly. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.2). The MAH took the opportunity to implement minor editorial updates; 2) extension of the shelf life after the first opening of Briviact (brivaracetam) oral solution (supported by real time data); 3) addition of a 1 mL oral syringe and its adaptor for the paediatric population. The package leaflet and labelling are updated in accordance

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.4. Caplacizumab - CABLIVI (CAP) - EMEA/H/C/004426/II/0035, Orphan

Applicant: Ablynx NV

PRAC Rapporteur: Jan Neuhauser

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on increased risk of bleeding and add blood and lymphatic system disorders to the list of adverse drug reactions (ADRs) with a frequency not known based on a safety evaluation report. The package leaflet and the RMP (version 2.0) are updated accordingly

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.5. Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/II/0020

Applicant: Merck Europe B.V.

PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: Update of sections 4.4 and 4.8 of the SmPC to add liver injury as a warning and as an undesirable effect with a frequency 'uncommon' based on a review of post-approval data in MAH’s safety database, non-clinical and clinical trial data and scientific literature on cladribine and liver injury and epidemiological data on hepatic injury in multiple sclerosis (MS)). The package leaflet is updated accordingly. This includes a proposal for a direct healthcare professional communication (DHPC) and communication plan developed to
inform of the risk of serious liver injury and new recommendations about liver function monitoring. The RMP (version 1.7) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.6. Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/II/0053, Orphan

**Applicant:** Otsuka Novel Products GmbH

**PRAC Rapporteur:** Laurence de Fays

**Scope:** Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) following the development of an improved methodology to identify relevant ADRs likely attributable to delamanid. The package leaflet and the RMP (version 3.6) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0069/G

**Applicant:** Biogen Netherlands B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** Grouped variations consisting of: 1) update of section 4.8 of the SmPC in order to add rhinorrhoea to the list of adverse drug reactions (ADRs) with a frequency not known based on a systematic review of information from clinical and non-clinical studies, post-marketing data and scientific literature. The package leaflet is updated accordingly; 2) update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study 109MS303 (ENDORSE) (listed as a category 3 study in the RMP): a dose-blind, multicentre, extension study to determine the long-term safety and efficacy of two doses of dimethyl fumarate (BG00012) monotherapy in subjects with relapsing-remitting multiple sclerosis. The RMP (version 11.1) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.8. Dimethyl fumarate - TECFIDERA (CAP) - EMEA/H/C/002601/II/0073

**Applicant:** Biogen Netherlands B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatrics patients from 10 years of age and over based on results from study 109MS306: an open-label, randomized, multicentre, multiple-dose, active-controlled, parallel-group, efficacy and safety study of dimethyl fumarate in children from 10 to less than 18 years of age with RRMS with optional open-label extension. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.3 of the SmPC are updated. The package leaflet and the RMP (version 11.4) is updated in accordance. The MAH requested an extension of the market protection of one additional year in line with the guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in accordance with Article 14(11) of Regulation (EC) 726/2004

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.9. **Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0027**

Applicant: Roche Registration GmbH
PRAC Rapporteur: Amelia Cupelli

Scope: Extension of indication to include treatment of adult and paediatric patients with haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.2 of the SmPC is updated to make clearer that the maintenance dose for Hemlibra (emicizumab) applies from week 5 of dosing. The package leaflet and the RMP (version 4.0) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.10. **Eptacog alfa (activated) - NOVOSEVEN (CAP) - EMEA/H/C/000074/II/0116**

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include treatment of severe postpartum haemorrhage for NovoSeven (eptacog alfa). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 8.0) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. **Etanercept - ENBREL (CAP) - EMEA/H/C/000262/II/0246**

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Eva Segovia

Scope: Update of section 5.1 of the SmPC in order to update clinical information based on final results obtained from the clinical paediatric study B1801023 (CLIPPER 2): an open label extension study to assess the long term safety of etanercept in children and adolescents with extended oligoarticular juvenile idiopathic arthritis, enthesitis related arthritis, or psoriatic arthritis who were previously enrolled in protocol 0881A1 3338 WW(B1801014). The RMP (version 7.5) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. **Galsulfase - NAGLAZYME (CAP) - EMEA/H/C/000640/II/0086**

Applicant: BioMarin International Limited
PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Submission of the final report from the mucopolysaccharidosis (MPS VI clinical surveillance programme (CSP) (listed as a specific obligation (SOB002) in Annex II): an observational CSP to characterise the natural progression of MPS VI; to evaluate the long-term safety and efficacy data from Naglazyme (galsulfase) treatment; to collect information on the effect of Naglazyme (galsulfase) treatment on lactation, growth and development of infants of Naglazyme (galsulfase) treated mothers and to evaluate the effects of Naglazyme (galsulfase) treatment on children under 5 years of age. The RMP (version 6.4) is updated
accordingly to remove gastrointestinal haemorrhage, hepatic impairment and thrombocytopenia from the list of important potential risks

**Action:** For adoption of PRAC Assessment Report

### 5.3.13. Givosiran - GIVLAARI (CAP) - EMEA/H/C/004775/II/0006, PRIME, Orphan

Applicant: Alnylam Netherlands B.V.

PRAC Rapporteur: Martin Huber

Scope: Update of section 4.8 of the SmPC to add 'blood homocysteine increase' as a new adverse drug reaction (ADR) and update of section 4.4 of the SmPC to add a related warning. The package leaflet and the RMP (version 1.1) are updated accordingly. In addition, the MAH took the opportunity to make editorial changes to the product information and to update the local representative details for Malta and Cyprus

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.14. Guselkumab - TREMFYA (CAP) - EMEA/H/C/004271/II/0031

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of sections 4.8 and 5.1 of the SmPC based on 2-year data from study CNT01959PSA3002: a phase 3, multicentre, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of guselkumab administered subcutaneously in subjects with active psoriatic arthritis. The RMP (version 8.2) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.15. Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/II/0069

Applicant: Janssen-Cilag International NV

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Update of section 4.4 of the SmPC to include information on fatal and serious cardiac arrhythmias and cardiac failure, relevant warnings and periodical monitoring of patients- following a safety assessment for increased risk of sudden death/cardiac death with the use of ibrutinib. The MAH took the opportunity to correct typographical errors throughout the product information. The package leaflet and the RMP (version 11) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.16. Idecabtagene vicleucel - ABECMA (CAP) - EMEA/H/C/004662/II/0010, PRIME, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG, ATMP

PRAC Rapporteur: Annika Folin

\[10\] Advanced therapy medicinal product
Scope: Update of section 5.1 of the SmPC in order to update efficacy information based on 24 month follow up data from the pivotal study submitted during the initial procedure, namely study BB2121-MM-001 (listed as a specific obligation in Annex II and in the RMP): a phase 2, multicentre study to determine the efficacy and safety of idecabtagene vicleucel (bb2121) in subjects with relapsed and refractory multiple myeloma. Annex II and the RMP (version 1.1) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

### 5.3.17. Lacosamide - LACOSAMIDE UCB (CAP) - EMEA/H/C/005243/WS2049/0009/G; VIMPAT (CAP) - EMEA/H/C/000863/WS2049/0091/G

Applicant: UCB Pharma S.A.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Grouped applications consisting of: 1) extension of indication to include patients from 1 month to 4 years of age for treatment of partial-onset seizures with or without secondary generalisation as monotherapy and adjunctive therapy. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The RMP (version 16.0) is updated accordingly; 2) change of a measuring or administration device; 3) extension of the shelf-life of the finished product. The package leaflet and labelling are updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.18. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/II/0009, Orphan

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Laurence de Fays

Scope: Extension of indication in β-thalassaemia to include adult patients with non-transfusion dependent β-thalassaemia (NTDT) for Reblozyl (luspatercept). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 1.1) are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.19. Olaparib - LYNPARZA (CAP) - EMEA/H/C/003726/II/0051/G

Applicant: AstraZeneca AB

PRAC Rapporteur: Amelia Cupelli

Scope: Extension of indication to include adjuvant treatment of breast cancer for Lynparza (for tablets). As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. In addition, section 4.8 of the SmPC for Lynparza (olaparib) hard capsules is revised based on the updated safety data analysis. The package leaflet and the RMP (version 23) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.3.20. Pembrolizumab - KEYTRUDA (CAP) - EMEA/H/C/003820/II/0117

Applicant: Merck Sharp & Dohme B.V.

PRAC Rapporteur: Menno van der Elst

Scope: Extension of indication to include a new indication in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 38.1) are updated accordingly.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.21. Ponatinib - ICLUSIG (CAP) - EMEA/H/C/002695/II/0061, Orphan

Applicant: Incyte Biosciences Distribution B.V.

PRAC Rapporteur: Annika Folin

Scope: Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on results from OPTIC study (AP24534-14-203) (listed as a specific obligation (SOB002) in Annex II): a randomised, open-label, phase 2 trial of ponatinib in patients with chronic myeloid leukaemia to characterise the efficacy and safety of ponatinib over a range of doses. The package leaflet and the RMP (version 21.0) are updated accordingly. The RMP (version 21.0) is updated as a response to the request for supplementary information (RSI).

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.22. Secukinumab - COSENTYX (CAP) - EMEA/H/C/003729/II/0079

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Eva Segovia

Scope: Extension of indication to include treatment of juvenile idiopathic arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 10.0) are updated in accordance.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.23. Semaglutide - OZEMPIC (CAP) - EMEA/H/C/004174/WS2141/0024; RYBELSUS (CAP) - EMEA/H/C/004953/WS2141/0018

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Annika Folin

Scope: Submission of the final report from study NN9535-4386 (SUSTAIN-11) (listed as a category 3 study in the RMP): a 52-week, multicentre, multinational, open-label, active controlled, two armed, parallel, randomised trial undertaken to investigate the effect on glycaemic control, body weight, safety and health-related quality of life of once-weekly semaglutide subcutaneous (sc) vs insulin aspart three times daily, both as add-on to metformin and optimised insulin glargine U100 treatment in subjects with inadequately
controlled type 2 diabetes mellitus (T2DM). The RMP (version 7.0) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.24. Setmelanotide - IMCIVREE (CAP) - EMEA/H/C/005089/II/0002/G, PRIME, Orphan

**Applicant:** Rhythm Pharmaceuticals Netherlands B.V.

**PRAC Rapporteur:** Marek Juracka

**Scope:** Grouped variations consisting of: 1) addition of a new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and the RMP (version 1.0) are updated accordingly; 2) addition of a new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Alström syndrome (AS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated accordingly. The package leaflet and the RMP (version 1.0) are updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.25. Tagraxofusp - ELZONRIS (CAP) - EMEA/H/C/005031/II/0009, Orphan

**Applicant:** Stemline Therapeutics B.V.

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Submission of the final report from study 20255431 (CRL-263114) (listed as a category 3 study in the RMP): a non-interventional, post-authorisation study on blood brain barrier (BBB) models in order to determine a potential toxicity biomarker to further investigate the risk of choroid plexus lesions - a characterisation of fixed choroid plexus samples from primate study MPI-2231-007 by immunohistochemistry with diphtheria toxin (DT), interleukin-3 receptor (CD123), interleukin-3 (IL-3) and immunoglobulin G (IgG) (in fulfilment of MEA 002). The RMP (version 2.0) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.26. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/II/0012

**Applicant:** Daiichi Sankyo Europe GmbH

**PRAC Rapporteur:** Marcia Sofia Sanches de Castro Lopes Silva

**Scope:** Extension of indication to include monotherapy treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior anti-HER2-based regimen for Enhertu (trastuzumab deruxtecan) based on final results from: 1) study DS8201-A-J202 (DESTINY Gastric01): a phase 2, multicentre, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma; 2) study DS8201-A-U205 (DESTINY Gastric02): a phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS 8201a) in HER2-positive, unresectable or metastatic gastric or GEJ adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP
(version 1.1) are updated accordingly. In addition, changes regarding the dosing recommendation for corticosteroid treatment and the protection of the infusion bag from light have been introduced.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.27. Upadacitinib - RINVOQ (CAP) - EMEA/H/C/004760/X/0012/G

**Applicant:** AbbVie Deutschland GmbH & Co. KG  
**PRAC Rapporteur:** Nikica Mirošević Skvrce  
**Scope:** Grouped applications consisting of: 1) extension application to add a new strength (45 mg) of the prolonged-release tablets; 2) include the treatment of adults with moderately to severely active ulcerative colitis who had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet, labelling and the RMP (version 6.) are updated in accordance.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 6. Periodic safety update reports (PSURs)

#### 6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

**6.1.1. Afamelanotide - SCENESSE (CAP) - PSUSA/00010314/202106**

**Applicant:** Clinuvel Europe Limited  
**PRAC Rapporteur:** Martin Huber  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

**6.1.2. Alpelisib - PIQRAY (CAP) - PSUSA/00010871/202105**

**Applicant:** Novartis Europharm Limited  
**PRAC Rapporteur:** Menno van der Elst  
**Scope:** Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

**6.1.3. Angiotensin II - GIAPREZA (CAP) - PSUSA/00010785/202106**

**Applicant:** Paion Deutschland GmbH  
**PRAC Rapporteur:** Menno van der Elst  
**Scope:** Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.4. Atidarsagene autotemcel - LIBMELDY (CAP) - PSUSA/00010899/202106

**Applicant:** Orchard Therapeutics (Netherlands) BV, ATMP¹¹

**PRAC Rapporteur:** Brigitte Keller-Stanislawski

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CAT and CHMP

### 6.1.5. Azacitidine - VIDAZA (CAP) - PSUSA/00000274/202105

**Applicant:** Bristol-Myers Squibb Pharma EEIG

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.6. Berotralstat - ORLADEYO (CAP) - PSUSA/00010930/202106

**Applicant:** BioCryst Ireland Limited

**PRAC Rapporteur:** Julia Pallos

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.7. Betibeglogene autotemcel - ZYNTEGLO (CAP) - PSUSA/00010769/202105

**Applicant:** bluebird bio (Netherlands) B.V., ATMP¹²

**PRAC Rapporteur:** Brigitte Keller-Stanislawski

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CAT and CHMP

### 6.1.8. Binimetinib - MEKTOVI (CAP) - PSUSA/00010717/202106

**Applicant:** Pierre Fabre Medicament

**PRAC Rapporteur:** Marcia Sofia Sanches de Castro Lopes Silva

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

¹¹ Advanced therapy medicinal product

¹² Advanced therapy medicinal product
6.1.9. Bromfenac - YELLOX (CAP) - PSUSA/00000436/202105

Applicant: Bausch Health Ireland Limited
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.10. Buprenorphine$^{13}$ - SIXMO (CAP) - PSUSA/00010778/202105

Applicant: L. Molteni & C. dei Fratelli Alitti Societa di Esercizio S.p.A.
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.11. Cannabidiol$^{14}$ - EPIDYOLEX (CAP) - PSUSA/00010798/202106

Applicant: GW Pharma (International) B.V.
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.12. Cholera vaccine, oral, live - VAXCHORA (CAP) - PSUSA/00010862/202106

Applicant: Emergent Netherlands B.V.
PRAC Rapporteur: Jean-Michel Dogné
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.13. Coronavirus (COVID-19) mRNA$^{15}$ vaccine (nucleoside-modified) - SPIKEVAX (CAP) - PSUSA/00010897/202106

Applicant: Moderna Biotech Spain, S.L.
PRAC Rapporteur: Hans Christian Siersted
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

---

$^{13}$ Implant(s) only
$^{14}$ Centrally authorised product(s) only
$^{15}$ Messenger ribonucleic acid
6.1.14. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - PSUSA/00010912/202106

Applicant: AstraZeneca AB
PRAC Rapporteur: Jean-Michel Dogné
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.15. Crisaborole - STAQUIS (CAP) - PSUSA/00010842/202106

Applicant: Pfizer Europe MA EEIG
PRAC Rapporteur: Eva Segovia
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.16. Dasatinib - SPRYCEL (CAP) - PSUSA/00000935/202106

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.17. Delafloxacin - QUOFENIX (CAP) - PSUSA/00010822/202106

Applicant: A. Menarini Industrie Farmaceutiche Riunite s.r.l.
PRAC Rapporteur: Željana Margan Koletić
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.18. Dengue tetravalent vaccine (live, attenuated) - DENVAXIA (CAP) - PSUSA/00010740/202106

Applicant: Sanofi Pasteur
PRAC Rapporteur: Sonja Hrabcik
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.19. Efmoreoctocog alfa - ELOCTA (CAP) - PSUSA/00010451/202106

Applicant: Swedish Orphan Biovitrum AB (publ)
PRAC Rapporteur: Sonja Hrabcik
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.20. Encorafenib - BRAFTOVI (CAP) - PSUSA/00010719/202106

Applicant: Pierre Fabre Medicament  
PRAC Rapporteur: Rugile Pilviniene  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.21. Entrectinib - ROZLYTREK (CAP) - PSUSA/00010874/202106

Applicant: Roche Registration GmbH  
PRAC Rapporteur: Menno van der Elst  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.22. Fenfluramine - FINTEPLA (CAP) - PSUSA/00010907/202106

Applicant: Zogenix ROI Limited  
PRAC Rapporteur: Martin Huber  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.23. Fluticasone furoate, vilanterol - RELVAR ELLIPTA (CAP); REVINTY ELLIPTA (CAP) - PSUSA/00010099/202105

Applicant(s): GlaxoSmithKline (Ireland) Limited  
PRAC Rapporteur: Maria del Pilar Rayon  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.24. Formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - TRIXEO AEROSPHERE (CAP) - PSUSA/00010908/202106

Applicant: AstraZeneca AB  
PRAC Rapporteur: Jan Neuhauser  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP
6.1.25. Galsulfase - NAGLAZYME (CAP) - PSUSA/00001515/202105

Applicant: BioMarin International Limited
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP


Applicant: Ammtek
PRAC Rapporteur: Eva Segovia
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.27. Human papillomavirus 9-valent vaccine (recombinant, adsorbed) - GARDASIL 9 (CAP) - PSUSA/00010389/202106

Applicant: MSD Vaccins
PRAC Rapporteur: Jean-Michel Dogné
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.28. Hydroxycarbamide17 - SIKLOS (CAP); XROMI (CAP) - PSUSA/00001692/202106

Applicant(s): Addmedica S.A.S. (Siklos), Nova Laboratories Ireland Limited (Xromi)
PRAC Rapporteur: Laurence de Fays
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.29. Imiglucerase - CEREZYME (CAP) - PSUSA/00001727/202105

Applicant: Genzyme Europe BV
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.30. Inclisiran - LEQVIO (CAP) - PSUSA/00010904/202106

Applicant: Novartis Europharm Limited

---

16 Centrally authorised product(s) only
17 Centrally authorised product(s) only
6.1.31. **Indacaterol, mometasone furoate - ATECTURA BREEZHALER (CAP); BEMRIST BREEZHALER (CAP) - PSUSA/00010850/202105**

Applicant(s): Novartis Europharm Limited
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.32. **Interferon beta-1a\(^{18}\) - AVONEX (CAP) - PSUSA/00010725/202105**

Applicant: Biogen Netherlands B.V.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.33. **Interferon beta-1a\(^{19}\) - REBIF (CAP) - PSUSA/00010726/202105**

Applicant: Merck Europe B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.34. **Larotrectinib - VITRAKVI (CAP) - PSUSA/00010799/202105**

Applicant: Bayer AG
PRAC Rapporteur: Rugile Pilviniene
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.35. **Latanoprost, netarsudil - ROCLANDA (CAP) - PSUSA/00010905/202106**

Applicant: Aerie Pharmaceuticals Ireland Limited
PRAC Rapporteur: Adam Przybylkowski
Scope: Evaluation of a PSUSA procedure

\(^{18}\) Intramuscular use only
\(^{19}\) Subcutaneous use only
**Action**: For adoption of recommendation to CHMP

### 6.1.36. Levodopa - INBRIJA (CAP) - PSUSA/00107800/202106

- **Applicant**: Acorda Therapeutics Ireland Limited
- **PRAC Rapporteur**: Nikica Mirošević Skvrce
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.37. Linagliptin - TRAJENTA (CAP); linagliptin, metformin - JENTADUETO (CAP) - PSUSA/00010427/202105

- **Applicant(s)**: Boehringer Ingelheim International GmbH
- **PRAC Rapporteur**: Menno van der Elst
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.38. Luspatercept - REBLOZYL (CAP) - PSUSA/00010860/202106

- **Applicant**: Bristol-Myers Squibb Pharma EEIG
- **PRAC Rapporteur**: Laurence de Fays
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.39. Migalastat - GALAFOLD (CAP) - PSUSA/00010507/202105

- **Applicant**: Amicus Therapeutics Europe Limited
- **PRAC Rapporteur**: Ulla Wändel Liminga
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.40. Netarsudil - RHOKIINSA (CAP) - PSUSA/00107812/202106

- **Applicant**: Aerie Pharmaceuticals Ireland Limited
- **PRAC Rapporteur**: Eva Segovia
- **Scope**: Evaluation of a PSUSA procedure
- **Action**: For adoption of recommendation to CHMP

### 6.1.41. Nevirapine - VIRAMUNE (CAP) - PSUSA/00002147/202105

- **Applicant**: Boehringer Ingelheim International GmbH
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.42. Nonacog beta pegol - REFIXIA (CAP) - PSUSA/00010608/202105

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.43. Nusinersen - SPINRAZA (CAP) - PSUSA/00010595/202105

Applicant: Biogen Netherlands B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.44. Obeticholic acid - OCALIVA (CAP) - PSUSA/00010555/202105

Applicant: Intercept Pharma International Limited
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.45. Onasemnogene abeparvovec - ZOLGENSMA (CAP) - PSUSA/00010848/202105

Applicant: Novartis Gene Therapies EU Limited, ATMP²⁰
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CAT and CHMP

### 6.1.46. Opicapone - ONGENTYS (CAP) - PSUSA/00010516/202106

Applicant: Bial - Portela & Cª, S.A.
PRAC Rapporteur: Maria del Pilar Rayon
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

²⁰ Advanced therapy medicinal product
6.1.47. Palivizumab - SYNAGIS (CAP) - PSUSA/00002267/202106

Applicant: AstraZeneca AB
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.48. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - ADJUPANRIX (CAP) - PSUSA/00002281/202105

Applicant: GlaxoSmithKline Biologicals SA
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.49. Pegvaliase - PALYNZIQ (CAP) - PSUSA/00010761/202105

Applicant: BioMarin International Limited
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.50. Pentosan polysulfate sodium\(^1\) - ELMIRON (CAP) - PSUSA/00010614/202106

Applicant: bene-Arzneimittel GmbH
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.51. Pertuzumab - PERJETA (CAP) - PSUSA/00010125/202106

Applicant: Roche Registration GmbH
PRAC Rapporteur: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

6.1.52. Pertuzumab, trastuzumab - PHESGO (CAP) - PSUSA/00010906/202106

Applicant: Roche Registration GmbH
PRAC Rapporteur: Brigitte Keller-Stanislawski

\(^1\) Centrally authorised product(s) only
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.53. Polatuzumab vedotin - POLIVY (CAP) - PSUSA/00010817/202106

Applicant: Roche Registration GmbH  
PRAC Rapporteur: Annika Folin  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.54. Propranolol - HEMANGIOL (CAP) - PSUSA/00010250/202104

Applicant: Pierre Fabre Dermatologie  
PRAC Rapporteur: Eva Segovia  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.55. Ravulizumab - ULTOMIRIS (CAP) - PSUSA/00010787/202106

Applicant: Alexion Europe SAS  
PRAC Rapporteur: Kimmo Jaakkola  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.56. Rilpivirine - EDURANT (CAP) - PSUSA/00009282/202105

Applicant: Janssen-Cilag International NV  
PRAC Rapporteur: Liana Gross-Martirosyan  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

### 6.1.57. Semaglutide - OZEMPIC (CAP); RYBELSUS (CAP) - PSUSA/00010671/202105

Applicant(s): Novo Nordisk A/S  
PRAC Rapporteur: Annika Folin  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CHMP

---

22 Centrally authorised product(s) only  
23 Oral use only
<table>
<thead>
<tr>
<th>Section</th>
<th>Product Name</th>
<th>Marketing Authorization Number</th>
<th>Applicant</th>
<th>PRAC Rapporteur</th>
<th>Scope</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1.58</td>
<td>Sildenafil</td>
<td>REVATIO (CAP) - PSUSA/00002700/202105</td>
<td>Upjohn EESV</td>
<td>Menno van der Elst</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.59</td>
<td>Sofosbuvir, velpatasvir</td>
<td>EPCLUSA (CAP) - PSUSA/00010524/202106</td>
<td>Gilead Sciences Ireland UC</td>
<td>Ana Sofia Diniz Martins</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.60</td>
<td>Sonidegib</td>
<td>ODOMZO (CAP) - PSUSA/00010408/202106</td>
<td>Sun Pharmaceutical Industries Europe B.V.</td>
<td>Željana Margan Koletić</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.61</td>
<td>Tozinameran</td>
<td>COMIRNATY (CAP) - PSUSA/00010898/202106</td>
<td>BioNTech Manufacturing GmbH</td>
<td>Menno van der Elst</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.62</td>
<td>Trametinib</td>
<td>MEKINIST (CAP) - PSUSA/00010262/202105</td>
<td>Novartis Europharm Limited</td>
<td>David Olsen</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td>6.1.63</td>
<td>Trastuzumab deruxtecan</td>
<td>ENHERTU (CAP) - PSUSA/00010894/202106</td>
<td>Daiichi Sankyo Europe GmbH</td>
<td>Marcia Sofia Sanches de Castro Lopes Silva</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

24 Indicated for the treatment of pulmonary hypertension
6.1.64. **Treosulfan** - TRECONDI (CAP) - PSUSA/00010777/202106

Applicant: medac Gesellschaft für klinische Spezialpräparate mbH

PRAC Rapporteur: Julia Pallos

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.1.65. **Turoctocog alfa pegol** - ESPEROCT (CAP) - PSUSA/00010782/202106

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.2. **PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)**

6.2.1. **Capsaicin** - QUTENZA (CAP); NAP - PSUSA/00000533/202105

Applicants: Grunenthal GmbH (Qutenza), various

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.2.2. **Imatinib** - GLIVEC (CAP); NAP - PSUSA/00001725/202105

Applicants: Novartis Europharm Limited (Glivec), various

PRAC Rapporteur: Eva Segovia

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

---

6.2.3. **Measles, mumps, rubella vaccines (live, attenuated)** - M-M-RVAXPRO (CAP); NAP - PSUSA/00001937/202105

Applicants: MSD Vaccins (M-M-RVAXPRO), various

PRAC Rapporteur: Brigitte Keller-Stanislawski

---

25 Centrally authorised product(s) only
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.2.4. Treprostinil - TREPULMIX (CAP); NAP - PSUSA/00003013/202105

Applicants: SciPharm Sarl (Trepulmix), various

PRAC Rapporteur: Zane Neikena

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.3. **PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only**

#### 6.3.1. 5 fluorouracil, salicylic acid (NAP) - PSUSA/00000008/202105

Applicant(s): various

PRAC Lead: Marek Juracka

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.2. Acipimox (NAP) - PSUSA/00000050/202105

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.3. Amino acid combinations, glucose, triglyceride combinations\(^{26}\), with or without electrolytes, mineral compounds (NAP)\(^{27, 28}\) - PSUSA/00010565/202106

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

---

\(^{26}\) E.g. olive oil, soya bean oil, fish oil

\(^{27}\) Intravenous (I.V.) application only

\(^{28}\) Except for the combination with nationally authorised product Numeta
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Applicant(s)</th>
<th>PRAC Lead</th>
<th>Scope</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.3.4.</td>
<td><strong>Amino acid combinations, glucose, with or without electrolytes, mineral compounds</strong>&lt;sup&gt;29&lt;/sup&gt; (NAP) - PSUSA/00010566/202106</td>
<td>various</td>
<td>Polona Golmajer</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CMDh</td>
</tr>
<tr>
<td>6.3.5.</td>
<td><strong>Benazepril, hydrochlorothiazide (NAP)</strong> - PSUSA/00000314/202105</td>
<td>various</td>
<td>Nathalie Gault</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CMDh</td>
</tr>
<tr>
<td>6.3.6.</td>
<td><strong>Bismuth subcitrate potassium, metronidazole, tetracycline (NAP)</strong> - PSUSA/00010199/202105</td>
<td>various</td>
<td>Nikica Mirošević Skvrce</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CMDh</td>
</tr>
<tr>
<td>6.3.7.</td>
<td><strong>Cidofovir (NAP)</strong> - PSUSA/00010558/202106</td>
<td>various</td>
<td>Rugilė Pilvinienė</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CMDh</td>
</tr>
<tr>
<td>6.3.8.</td>
<td><strong>Clevidipine (NAP)</strong> - PSUSA/00010288/202105</td>
<td>various</td>
<td>Jan Neuhauser</td>
<td>Evaluation of a PSUSA procedure</td>
<td>For adoption of recommendation to CMDh</td>
</tr>
<tr>
<td>6.3.9.</td>
<td><strong>Daunorubicin (NAP)</strong> - PSUSA/00000936/202106</td>
<td>various</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>29</sup> Intravenous (I.V.) application only
6.3.10. Flunarizine (NAP) - PSUSA/00001416/202105

Applicant(s): various
PRAC Lead: Ana Sofia Diniz Martins
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.11. Goserelin (NAP) - PSUSA/00001562/202105

Applicant(s): various
PRAC Lead: Martin Huber
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.12. Human hemin (NAP) - PSUSA/00001629/202105

Applicant(s): various
PRAC Lead: Tiphaine Vaillant
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.13. Iodine (131I) iobenguane (NAP) - PSUSA/00001764/202105

Applicant(s): various
PRAC Lead: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.14. Lactulose (NAP) - PSUSA/00001821/202105

Applicant(s): various
PRAC Lead: Ilaria Baldelli
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh
6.3.15. **Lanreotide (NAP) - PSUSA/00001826/202105**

Applicant(s): various  
PRAC Lead: Zane Neikena  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.16. **Levofloxacin, dexamethasone\(^{30}\) (NAP) - PSUSA/00010881/202106**

Applicant(s): various  
PRAC Lead: Ilaria Baldelli  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.17. **Levonorgestrel\(^{31}\) (NAP) - PSUSA/00010828/202105**

Applicant(s): various  
PRAC Lead: Martin Huber  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.18. **Loperamide (NAP); loperamide, simeticone (NAP) - PSUSA/00010665/202105**

Applicant(s): various  
PRAC Lead: Adam Przybylkowski  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.19. **Milnacipran (NAP) - PSUSA/00002063/202104**

Applicant(s): various  
PRAC Lead: Tiphaine Vaillant  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.20. **Misoprostol\(^{32}\) (NAP) - PSUSA/00010291/202106**

Applicant(s): various

---

\(^{30}\) Formulation(s) for ocular use only  
\(^{31}\) All indications except emergency contraception  
\(^{32}\) Gastrointestinal indication(s) only
6.3.21. **Misoprostol**33 (NAP) - PSUSA/00010353/202105

- **Applicant(s):** various
- **PRAC Lead:** Anette Kirstine Stark
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.22. **Moxifloxacin**34 (NAP) - PSUSA/00002094/202105

- **Applicant(s):** various
- **PRAC Lead:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.23. **Nadifloxacin** (NAP) - PSUSA/00002102/202105

- **Applicant(s):** various
- **PRAC Lead:** Martin Huber
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.24. **Olodaterol, tiotropium** (NAP) - PSUSA/00010489/202105

- **Applicant(s):** various
- **PRAC Lead:** Menno van der Elst
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

6.3.25. **Pamidronate** (NAP) - PSUSA/00002269/202105

- **Applicant(s):** various
- **PRAC Lead:** Menno van der Elst
- **Scope:** Evaluation of a PSUSA procedure
- **Action:** For adoption of recommendation to CMDh

---

33 Gynaecological indication(s) only - labour induction
34 Topical ophthalmic use only
6.3.26. Paracetamol\(^{35}\) (NAP) - PSUSA/00002311/202105

Applicant(s): various  
PRAC Lead: Tiphaine Vaillant  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.27. Phenylpropanolamine (NAP) - PSUSA/00010483/202106

Applicant(s): various  
PRAC Lead: Eva Jirsová  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.28. Pholcodine (NAP) - PSUSA/00002396/202105

Applicant(s): various  
PRAC Lead: Nathalie Gault  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.29. Ranitidine (NAP) - PSUSA/00002610/202105

Applicant(s): various  
PRAC Lead: Ilaria Baldelli  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.30. Remifentanil (NAP) - PSUSA/00002617/202105

Applicant(s): various  
PRAC Lead: Martin Huber  
Scope: Evaluation of a PSUSA procedure  
**Action:** For adoption of recommendation to CMDh

6.3.31. Triglyceride combinations\(^{36}\), with or without mineral compounds, electrolytes\(^{37}\) (NAP) - PSUSA/00010648/202106

Applicant(s): various

\(^{35}\) Intravenous (I.V.) formulation only  
\(^{36}\) E.g. olive oil, soya bean oil, fish oil  
\(^{37}\) Intravenous (I.V.) application only
PRAC Lead: Nikica Mirošević Skvrce
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

### 6.4. Follow-up to PSUR/PSUSA procedures

#### 6.4.1. Pregabalin - LYRICA (CAP) - EMEA/H/C/000546/LEG 056

Applicant: Upjohn EESV
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Review of Northern Ireland (NI) Health and Social Care Board letter to prescribers on the removal of pregabalin from NI formulary for neuropathic pain, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002511/202101) adopted in September 2021
Action: For adoption of advice to CHMP

#### 6.4.2. Pregabalin - PREGABALIN PFIZER (CAP) - EMEA/H/C/003880/LEG 008

Applicant: Upjohn EESV
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Review of Northern Ireland (NI) Health and Social Care Board letter to prescribers on the removal of pregabalin from NI formulary for neuropathic pain, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002511/202101) adopted in September 2021
Action: For adoption of advice to CHMP

#### 6.4.3. Tenofovir disoproxil - VIREAD (CAP) - EMEA/H/C/000419/LEG 278

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Nathalie Gault
Scope: Detailed analysis of cases of neural tube defects following exposure to tenofovir disoproxil fumarate (TDF) in pregnancy including information on concomitant treatment, as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002892/202003) adopted in November 2020
Action: For adoption of advice to CHMP

### 6.5. Variation procedure(s) resulting from PSUSA evaluation

#### 6.5.1. Arsenic trioxide - TRISENOX (CAP) - EMEA/H/C/000388/II/0076

Applicant: Teva B.V.
PRAC Rapporteur: Tiphaine Vaillant
Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy and contraception in male patients as requested in the conclusions of the last PSUR single assessment (PSUSA) procedure (PSUSA/00000235/202009) adopted in June 2021. The package leaflet is updated accordingly.

**Action:** For adoption of PRAC Assessment Report

### 6.5.2. Baricitinib - OLMIANT (CAP) - EMEA/H/C/004085/II/0031

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Update of section 4.4 of the SmPC in order to add new warnings on major adverse cardiac events (MACE) and amend an existing warning on malignancy and venous thromboembolism (VTE) as requested in the conclusions of the last PSUR single assessment (PSUSA) procedure (PSUSA/00010578/202102) adopted in September 2021 and based on interim results from study I4V-MC-B023: a retrospective observational study to compare baricitinib relative to the standard of care. The package leaflet is updated accordingly. The RMP (version 13.1) has also been submitted. In addition, the MAH has submitted a proposal for a direct healthcare professional communication (DHPC) and communication plan.

**Action:** For adoption of PRAC Assessment Report

### 6.5.3. Clofarabine - EVOLTRA (CAP) - EMEA/H/C/000613/II/0075

Applicant: Genzyme Europe BV

PRAC Rapporteur: Tiphaine Vaillant

Scope: Update of section 4.6 of the SmPC as requested in the conclusions of the last PSUR single assessment (PSUSA) procedure (PSUSA/00000805/202012) to revise the section on fertility, pregnancy and lactation considering the recommendations of the Safety Working Party (SWP) as reflected in the SWP recommendations on the duration of contraception following the end of treatment with a genotoxic drug and available data. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet and to bring the product information in line with the latest quality review of documents (QRD) template (version 10.2).

**Action:** For adoption of PRAC Assessment Report

### 6.5.4. Coronavirus (COVID-19) vaccine (Ad26.COV2-S, recombinant) - COVID-19 VACCINE JANSSEN (CAP) - EMEA/H/C/005737/II/0035

Applicant: Janssen-Cilag International N.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Update of section 4.8 of the SmPC in order to add transverse myelitis to the list of adverse drug reactions (ADR) with a frequency not known based on the PRAC request from the post-authorisation measures MEA 14.5 and MEA 14.6 (sixth and seventh monthly summary safety reports (MSSR) covering August 2021 and September 2021 respectively) and update of section 4.4 of the SmPC in order to amend the wording on thrombosis and thrombocytopenia syndrome (TTS) as requested in the outcome of post-authorisation.
measure MEA 14.5. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to implement an editorial quality review document (QRD) comment in the labelling following completion of variation II/0014 in September 2021.

**Action:** For adoption of PRAC Assessment Report

### 6.5.5. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0025

Applicant: Roche Registration GmbH  
PRAC Rapporteur: Amelia Cupelli  
Scope: Update of sections 4.4, 4.8 and 5.1 of the SmPC concerning immunogenicity and loss of efficacy due to anti-emicizumab antibodies as requested in the conclusions of the latest periodic safety update report single assessment (PSUSA) procedure (PSUSA/00010668/202011) adopted in June 2021, together with a review of haemorrhagic cases as requested in the conclusions of the PSUSA procedure (PSUSA/00010668/202005) finalised in January 2021. The RMP (version 3.0) is updated accordingly.

**Action:** For adoption of PRAC Assessment Report

### 6.5.6. Tozinameran - COMIRNATY (CAP) - EMEA/H/C/005735/II/0080

Applicant: BioNTech Manufacturing GmbH  
PRAC Rapporteur: Menno van der Elst  
Scope: Update of section 4.4 of the SmPC in order to amend an existing warning on anxiety-related reactions to add ‘numbness’ based on the outcome of the ninth monthly summary safety report (MSSR) (MEA 002.8) finalised in October 2021. In addition, the MAH took the opportunity to make minor editorial changes throughout the product information.

**Action:** For adoption of PRAC Assessment Report

### 6.6. Expedited summary safety reviews

#### 6.6.1. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 027.7

Applicant: AstraZeneca AB  
PRAC Rapporteur: Jean-Michel Dogné  
Scope: Eighth expedited summary safety report (SSR) for Vaxzevria (COVID-19 vaccine (ChAdOx1-S [recombinant])) during the coronavirus disease (COVID-19) pandemic

**Action:** For adoption of PRAC Assessment Report

---

38 Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC.
7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)\(^{39}\)

7.1.1. Lenalidomid - REVLIMID (CAP) - EMEA/H/C/PSA/S/0075.1

Applicant: Bristol-Myers Squibb Pharma EEIG
PRAC Rapporteur: Tiphaine Vaillant
Scope: MAH’s response to PSA/S/0075 [substantial amendment to a protocol previously agreed in December 2017 (PSA/S/0016.2) for study CC-5013-MDS-012: a post-authorisation, non-interventional, retrospective, drug-utilisation study (DUS) to describe the pattern of use of lenalidomide in patients with myelodysplastic syndromes (MDS)] as per the request for supplementary information (RSI) adopted in September 2021
Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Parathyroid hormone – NATPAR (CAP) - EMEA/H/C/PSA/S/0053.4

Applicant: Takeda Pharmaceuticals International AG
PRAC Rapporteur: Rhea Fitzgerald
Scope: MAH’s response to PSA/S/0053.3 [substantial amendment to a protocol previously agreed in March 2018 (PSA/S/0026) for study PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism): a registry for subjects with chronic hypoparathyroidism to explore physicians advancing disease knowledge in hypoparathyroidism] as per the request for supplementary information (RSI) adopted in September 2021
Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. Selumetinib - KOSELUGO (CAP) - EMEA/H/C/PSP/S/0095.1

Applicant: AstraZeneca AB
PRAC Rapporteur: Annika Folin
Scope: MAH’s response to PSA/S/0053.3 [protocol for a PASS of paediatric patients initiating selumetinib: a multiple-country prospective cohort study] as per the request for supplementary information (RSI) adopted in November 2021
Action: For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. Tisagenlecleucel - KYMRIAH (CAP) - EMEA/H/C/PSA/S/0080

Applicant: Novartis Europharm Limited, ATMP\(^{40}\)
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Substantial amendment to a protocol previously agreed in November 2019

---

\(^{39}\) In accordance with Article 107n of Directive 2001/83/EC
\(^{40}\) Advanced therapy medicinal product
(PSP/S/0066.3) for registry study CCT019B2401 to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.5. Valproate\(^{41}\) (NAP) - EMEA/H/N/PSP/J/0074.4

**Applicant:** Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** Interim report for a joint observational study to evaluate and identify the best practices for switching of valproate in clinical practice, as required in the outcome of the referral procedure under Article 31 of Directive 2001/83/EC on valproate-containing products completed in February 2018 (EMEA/H/A-31/1454)]

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.6. Valproate\(^{42}\) (NAP) - EMEA/H/N/PSA/J/0077

**Applicant:** Sanofi-Aventis Recherche & Développement (on behalf of a consortium)

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** Substantial amendment to a protocol previously agreed in July 2020 (PSP/0074.3) for an observational study to evaluate and identify the best practices for switching of valproate in clinical practice

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.1.7. Voretigene neparvovec - LUXTURNA (CAP) - EMEA/H/C/PSA/S/0081

**Applicant:** Novartis Europharm Ltd, ATMP\(^{43}\)

**PRAC Rapporteur:** Brigitte Keller-Stanislawski

**Scope:** Substantial amendment to a protocol previously agreed in March 2021 (PSA/S/0066) for a post-authorisation multicentre, multinational, longitudinal, observational safety registry study to collect long-term safety information associated with voretigene neparvovec (vector and/or transgene), its subretinal injection procedure, the concomitant use of corticosteroids, or a combination of these procedures and products

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

---

\(^{41}\) Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

\(^{42}\) Valproic acid, sodium valproate, valproate pivoxil, valproate semisodium, valpriomide, valproate bismuth, calcium valproate, valproate magnesium

\(^{43}\) Advanced therapy medicinal product
7.2. **Protocols of PASS non-imposed in the marketing authorisation(s)**

7.2.1. **Alpelisib - PIQRAY (CAP) - EMEA/H/C/004804/MEA 003.1**

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Menno van der Elst

Scope: MAH's response to MEA 003.1 [protocol for study CBYL719C2005: a survey among healthcare professionals treating patients with metastatic breast cancer in selected European countries to evaluate their knowledge on management of hyperglycaemia when using Piqray (alpelisib) as included in the educational material] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

7.2.2. **Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 004.2**

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 004.1 [protocol for study 215162 (listed as a category 3 study in the RMP): a prospective observational cohort study to monitor for hepatotoxicity and regimen discontinuation due to liver related adverse events among patients initiating cabotegravir-containing antiretroviral regimen [final clinical study report (CSR): expected in March 2027]] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

7.2.3. **Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 005.2**

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 005.1 [protocol for study 215163: a study on pregnancy and neonatal outcomes following prenatal exposure to cabotegravir long acting (CAB LA) – data from the European Pregnancy and Paediatric human immunodeficiency virus (HIV) Cohort Collaboration (EPPICC)] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

7.2.4. **Cabotegravir - VOCABRIA (CAP) - EMEA/H/C/004976/MEA 006.2**

Applicant: ViiV Healthcare B.V.

PRAC Rapporteur: Martin Huber

Scope: MAH's response to MEA 006.1 [protocol for study 215325: a study on pregnancy and

---

44 In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
neonatal outcomes following prenatal exposure to cabotegravir – data from the Antiretroviral Pregnancy Registry (APR)) as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

### 7.2.5. Coronavirus (COVID-19) mRNA\(^{45}\) vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 004.4

**Applicant:** Moderna Biotech Spain, S.L.

**PRAC Rapporteur:** Hans Christian Siersted

**Scope:** MAH’s response to MEA 004.3 [protocol for study mRNA-1273-P904 (study 1) (listed as a category 3 study in the RMP): a post-authorisation active surveillance safety study using secondary data to monitor real-world safety of Spikevax (COVID-19 mRNA-1273 vaccine) in Europe - an enhanced pharmacovigilance study to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals in European populations and electronic database assessment of use in pregnant women [final clinical study report (CSR) expected in December 2023]] as per the request for supplementary information (RSI) adopted in July 2021 together with the first study progress report for study mRNA-1273-P904

**Action:** For adoption of advice to CHMP

### 7.2.6. Isatuximab - SARCLISA (CAP) - EMEA/H/C/004977/MEA 002.2

**Applicant:** Sanofi-aventis groupe

**PRAC Rapporteur:** Eva Segovia

**Scope:** MAH’s response to MEA 002.1 [protocol for study SARSAC09715: a non-interventional PASS survey to evaluate the effectiveness of isatuximab educational materials to minimise the risk of interference for blood typing (minor antigen) (positive indirect Coombs’ test)] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

### 7.2.7. Patisiran - ONPATTRO (CAP) - EMEA/H/C/004699/MEA 003.2

**Applicant:** Alnylam Netherlands B.V.

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** Update to a previously agreed protocol and interim study report for study ALN-TTR02-010: patisiran- lipid nanoparticle (LNP) pregnancy surveillance programme (PSP) to collect primary data on pregnant women from the US, the United Kingdom (UK), France, Spain, Italy, Portugal and Germany, and other potential countries, who have been exposed to patisiran during the exposure window, defined as 12 weeks prior to their last menstrual period (LMP), or at any time during pregnancy as well as to collect and analyse information pertaining to pregnancy complications and birth outcomes in women exposed to patisiran

\(^{45}\) Messenger ribonucleic acid
during pregnancy

**Action:** For adoption of advice to CHMP

### 7.2.8. Ponesimod - PONVORY (CAP) - EMEA/H/C/005163/MEA 001

**Applicant:** Janssen-Cilag International N.V.

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Protocol for study PCSNSP004001 (listed as a category 3 study in the RMP): ponesimod pregnancy outcomes enhanced monitoring (POEM) - pregnancy outcomes programme utilising enhanced pharmacovigilance monitoring to evaluate the potential risk of reproductive and embryofetal toxicity in pregnant women exposed to ponesimod (from initial opinion/marketing authorisation)

**Action:** For adoption of advice to CHMP

### 7.2.9. Risankizumab - SKYRIZI (CAP) - EMEA/H/C/004759/MEA 001.4

**Applicant:** AbbVie Deutschland GmbH & Co. KG

**PRAC Rapporteur:** Liana Gross-Martirosyan

**Scope:** Substantial amendment to a protocol previously agreed in January 2021 for study P19-633: a post-marketing registry-based prospective cohort study of long-term safety of risankizumab in real world setting in Denmark and Sweden [final study report expected in December 2031] together with a statistical analysis plan (SAP)

**Action:** For adoption of advice to CHMP

### 7.2.10. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 002.7

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Substantial amendment to a previously agreed protocol for study CLCZ696B2014 (PASS 1) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to characterise the risk of angioedema and other specific safety events of interest in association with the use of Entresto/Neparvis (sacubitril/valsartan) in adult patients with heart failure [final report expected in Q4 2022] together with a statistical analysis plan (SAP)

**Action:** For adoption of advice to CHMP

### 7.2.11. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 002.4

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Substantial amendment to a previously agreed protocol for study CLCZ696B2014 (PASS 1) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to characterise the risk of angioedema and other
specific safety events of interest in association with the use of Entresto/Neparvis (sacubitril/valsartan) in adult patients with heart failure [final report expected in Q4 2022] together with a statistical analysis plan (SAP)

**Action:** For adoption of advice to CHMP

### 7.2.12. Somapacitan - SOGROYA (CAP) - EMEA/H/C/005030/MEA 002.1

Applicant: Novo Nordisk A/S
PRAC Rapporteur: Martin Huber

Scope: MAH’s response to MEA 002 [protocol for study NN8640-4515: a multinational, multicentre, prospective, open label, single-arm, observational, non-interventional PASS to investigate long-term safety of somapacitan in adults with growth hormone deficiency (AGHD) under normal clinical practice conditions (from initial marketing authorisation/opinion)] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

### 7.2.13. Trastuzumab deruxtecan - ENHERTU (CAP) - EMEA/H/C/005124/MEA 003.1

Applicant: Daiichi Sankyo Europe GmbH
PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: MAH’s response to MEA 003 [protocol for an EU survey of relevant healthcare professionals on the understanding of key risk minimisation measures pertaining to interstitial lung disease (ILD)/pneumonitis with trastuzumab deruxtecan treatment (from initial marketing authorisation/opinion)] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

### 7.3. Results of PASS imposed in the marketing authorisation(s)

#### 7.3.1. Hydroxyethyl starch (HES) (NAP) - EMEA/H/N/PSR/J/0031

Applicant(s): Fresenius Kabi Deutschland GmbH (Volulyte, Voluven), B. Braun Melsungen AG (Tetraspan, Venofundin)
PRAC Rapporteur: Nathalie Gault

Scope: MAH’s response to PSR/J/0031 [results for a joint retrospective, multinational, drug utilisation study (DUS) to assess the non-adherence of physicians in hydroxyethyl starch (HES) accredited hospitals to the approved European product information [regarding indication for use, contraindications and posology (dosage)] for HES 130-containing medicinal products in clinical routine after implementation of a set of risk minimisation measures as required in the outcome of the referral procedure under Article 107i of Directive 2001/83/EC for HES completed in 2018 (EMEA/H/A-107I/1457)] as per the request

---

46 In accordance with Article 107p-q of Directive 2001/83/EC
for supplementary information (RSI) adopted in October 2021

**Action:** For adoption of recommendation to CMDh (or request for supplementary information (RSI))

### 7.4. Results of PASS non-imposed in the marketing authorisation(s)\(^{47}\)

#### 7.4.1. Apremilast - OTEZLA (CAP) - EMEA/H/C/003746/II/0039

**Applicant:** Amgen Europe B.V.  
**PRAC Rapporteur:** Eva Segovia  
**Scope:** Submission of the final study report (CSR) from the UK Clinical Practice Research Database (CPRD) (listed as a category 3 study in the RMP): an observational study to assess the long-term data of apremilast in patients with psoriasis and psoriatic arthritis. The RMP (version 14.0) is updated accordingly  

**Action:** For adoption of PRAC Assessment Report

#### 7.4.2. Emicizumab - HEMLIBRA (CAP) - EMEA/H/C/004406/II/0028

**Applicant:** Roche Registration GmbH  
**PRAC Rapporteur:** Amelia Cupelli  
**Scope:** Submission of the final study report for BO40853 (listed as a category 3 study in the RMP): a survey to prescribers and patients/carers to evaluate awareness, knowledge, and compliance to additional risk minimisation measures. The RMP (version 4.0) is updated accordingly

**Action:** For adoption of PRAC Assessment Report

#### 7.4.3. Infliximab - REMICADE (CAP) - EMEA/H/C/000240/II/0231

**Applicant:** Janssen Biologics B.V.  
**PRAC Rapporteur:** Ulla Wändel Liminga  
**Scope:** Submission of the final report of the Remicade (infliximab) Anti-Rheumatic Therapy in Sweden (ARTIS) register study. The RMP (version 20.1) is updated accordingly and with revisions agreed in previous procedures

**Action:** For adoption of PRAC Assessment Report

#### 7.4.4. Influenza vaccine surface antigen inactivated prepared in cell cultures - FLUCELVAX TETRA (CAP) - EMEA/H/C/004814/II/0023

**Applicant:** Seqirus Netherlands B.V.  
**PRAC Rapporteur:** Brigitte Keller-Stanislawski

---

\(^{47}\) In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
Scope: Update of section 4.6 of the SmPC in order to update information on pregnancy registry 130_110B (listed as a category 3 study in the RMP) on use in pregnant and breastfeeding women to evaluate pregnancy outcomes. The package leaflet and the RMP (version 3.1) are updated accordingly

**Action:** For adoption of PRAC Assessment Report

### 7.4.5. Insulin glargine, lixisenatide - SULIQUA (CAP) - EMEA/H/C/004243/II/0024

**Applicant:** Sanofi-aventis groupe

**PRAC Rapporteur:** Menno van der Elst

Scope: Submission of the final clinical study report (CSR) of study INSLIC08571 (listed as a category 3 study in the RMP): a survey to evaluate the knowledge and understanding of the key safety messages in the healthcare professional guide and the patient guide (in fulfilment of MEA 002). The RMP (version 6.0) is updated accordingly

**Action:** For adoption of PRAC Assessment Report

### 7.4.6. Naloxegol - MOVENTIG (CAP) - EMEA/H/C/002810/II/0034

**Applicant:** Kyowa Kirin Holdings B.V.

**PRAC Rapporteur:** Rhea Fitzgerald

Scope: Submission of the final report from study D3820R00006 (listed as a category 3 study in the RMP): an observational drug utilisation in selected European populations. The RMP (version 7.0) is updated accordingly

**Action:** For adoption of PRAC Assessment Report

### 7.4.7. Susoctocog alfa - OBIZUR (CAP) - EMEA/H/C/002792/II/0043

**Applicant:** Baxalta Innovations GmbH

**PRAC Rapporteur:** Brigitte Keller-Stanislawski

Scope: Submission of the final report from study US PASS 241302 (EUPAS36659) (listed as a category 3 study in the RMP): a post-marketing non-interventional safety evaluation of Obizur (susoctocog alfa) in the treatment of bleeding episodes for patients with acquired haemophilia A (AHA) to determine the incidence of therapy-related serious adverse events (SAEs) in patients with AHA who are prescribed and treated with Obizur (susoctocog alfa) in routine clinical practice. The RMP (version 5.0) is updated accordingly

**Action:** For adoption of PRAC Assessment Report

### 7.4.8. Teriflunomide - AUBAGIO (CAP) - EMEA/H/C/002514/II/0038

**Applicant:** Sanofi-aventis groupe

**PRAC Rapporteur:** Martin Huber

Scope: Submission of the final study report for study OBS12753 (listed as a category 3 study in the RMP): a prospective cohort study of long-term safety of teriflunomide in...
multiple sclerosis patients in Europe. The RMP (version 7.1) is updated accordingly.

**Action:** For adoption of PRAC Assessment Report

### 7.4.9. Trastuzumab - ONTRUZANT (CAP) - EMEA/H/C/004323/II/0036

**Applicant:** Samsung Bioepis NL B.V.

**PRAC Rapporteur:** Brigitte Keller-Stanislawski

**Scope:** Submission of the final report from clinical study SB3-G31-BC-E (listed as a category 3 study in the RMP): an observational cohort study assessing the long-term cardiac safety (for cardiac safety and survival cohort) and survival (survival only cohort and cardiac safety and survival cohort) in patients who received treatment with trastuzumab. The RMP (version 5.0) is updated accordingly.

**Action:** For adoption of PRAC Assessment Report

### 7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

#### 7.5.1. Aclidinium - BRETARIS GENUAIR (CAP) - EMEA/H/C/002706/ANX 001.10

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** MAH’s response to ANX 001.9 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of aclidinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021.

**Action:** For adoption of advice to CHMP

#### 7.5.2. Aclidinium - EKLIRA GENUAIR (CAP) - EMEA/H/C/002211/ANX 001.10

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** Adam Przybylkowski

**Scope:** MAH’s response to ANX 001.9 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of aclidinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021.

**Action:** For adoption of advice to CHMP
7.5.3. **Aclidinium, formoterol fumarate dihydrate - BRIMICA GENUAIR (CAP) - EMEA/H/C/003969/ANX 003.7**

Applicant: AstraZeneca AB
PRAC Rapporteur: Adam Przybylkowski
Scope: MAH’s response to ANX 003.6 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of acilidinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

7.5.4. **Aclidinium, formoterol fumarate dihydrate - DUAKLIR GENUAIR (CAP) - EMEA/H/C/003745/ANX 003.7**

Applicant: AstraZeneca AB
PRAC Rapporteur: Adam Przybylkowski
Scope: MAH’s response to ANX 003.6 [third interim report for study D6560R00004, formerly M/34273/44, (listed as a category 1 in Annex II and the RMP): an observational study evaluating the risk of cardiovascular endpoints of acilidinium bromide-containing products versus other chronic obstructive pulmonary disease (COPD) medications in COPD patients - sub-study report addressing the acute myocardial infarction (AMI) report and stroke components of the PASS programme] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

7.5.5. **Burosumab - CRYSVITA (CAP) - EMEA/H/C/004275/MEA 004.3**

Applicant: Kyowa Kirin Holdings B.V.
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: First interim report for study 2019-36-EU-CRY (EUPAS32190): a non-interventional study in the treatment of children >1 year of age and adolescents with X-linked hypophosphataemia (XLH) to assess the long term safety of Crysvita (burosumab) during routine clinical care using data collected in a European disease registry for XLH [final report expected in December 2028]

**Action:** For adoption of advice to CHMP

7.5.6. **Cangrelor - KENGREXAL (CAP) - EMEA/H/C/003773/MEA 002.4**

Applicant: Chiesi Farmaceutici S.p.A.
PRAC Rapporteur: Amelia Cupelli
Scope: Second interim report for study DFIDM-1801 (ARCANGELO (i)taLian pRospective
study on CANGrELOr): a multicentre prospective observational study of acute coronary syndrome patients undergoing percutaneous coronary intervention (PCI) who receive cangrelor and transition to either clopidogrel, prasugrel or ticagrelor

**Action:** For adoption of advice to CHMP

### 7.5.7. Cladribine - MAVENCLAD (CAP) - EMEA/H/C/004230/MEA 002.2

**Applicant:** Merck Europe B.V.

**PRAC Rapporteur:** Marcia Sofia Sanches de Castro Lopes Silva

**Scope:** First interim report for study MS 700568-0002 (listed as a category 3 study in the RMP): a prospective, observational cohort study evaluating the safety profile, in terms of incidence of adverse events of special interest, in patients with highly active relapsing multiple sclerosis (RMS) newly started on oral cladribine [final report expected in Q2 2034]

**Action:** For adoption of advice to CHMP

### 7.5.8. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 005.2

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** First interim report for study D8111R00003: a phase 4 non-interventional enhanced active surveillance study of adults vaccinated with Vaxzevria (AZD1222 – COVID-19 vaccine)

**Action:** For adoption of advice to CHMP

### 7.5.9. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 006.2

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** First quarterly report for study C-VIPER: a pregnancy registry of women exposed to Vaxzevria (AZD1222 – COVID-19 vaccine) immediately before or during pregnancy (from initial opinion/marketing authorisation(s) (MA))

**Action:** For adoption of advice to CHMP

### 7.5.10. Coronavirus (COVID-19) vaccine (ChAdOx1-S [recombinant]) - VAXZEVRIA (CAP) - EMEA/H/C/005675/MEA 007.3

**Applicant:** AstraZeneca AB

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** First progress report for study D8111R00006: a post-authorisation/post-marketing observational study using existing secondary health data sources to evaluate the association between exposure to Vaxzevria (AZD1222) and safety concerns
Action: For adoption of advice to CHMP

7.5.11. Coronavirus (COVID-19) mRNA\textsuperscript{48} vaccine (nucleoside-modified) - SPIKEVAX (CAP) - EMEA/H/C/005791/MEA 003.4

Applicant: Moderna Biotech Spain, S.L.
PRAC Rapporteur: Hans Christian Siersted
Scope: Third Interim report for a study (listed as a category 3 study in the RMP): a post authorisation safety of Spikevax (SARS-CoV-2 mRNA-1273 vaccine) in the US - an enhanced pharmacovigilance study (listed as a category 3 study in the RMP) to provide additional evaluation of adverse events of special interest (AESI) and emerging validated safety signals [final clinical study report (CSR) expected in June 2023] (from initial opinion/marketing authorisation (MA))

Action: For adoption of advice to CHMP

7.5.12. Ketoconazole - KETOCONAZOLE HRA (CAP) - EMEA/H/C/003906/ANX 002.8

Applicant: HRA Pharma Rare Diseases
PRAC Rapporteur: Željana Margan Koletić
Scope: Fourth interim annual report for a prospective, multi-country, observational registry study to collect clinical information on patients with endogenous Cushing’s syndrome exposed to ketoconazole using the existing European registry on Cushing’s syndrome (ERCUSYN) to assess drug utilisation pattern and to document the safety (e.g. hepatotoxicity, QT prolongation) and effectiveness of ketoconazole

Action: For adoption of advice to CHMP

7.5.13. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 001.3

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: Second interim report for study OP0005: a European non-interventional PASS to study the adherence to the risk minimisation measures (RMMs) in the product information by estimating the compliance with contraindications and target indication(s) amongst incident romosozumab users, and analysing the utilisation pattern using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in March 2026]

Action: For adoption of advice to CHMP

7.5.14. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 002.3

Applicant: UCB Pharma S.A.
PRAC Rapporteur: Tiphaine Vaillant
Scope: Second interim report for study OP0004: a European non-interventional PASS to

\textsuperscript{48} Messenger ribonucleic acid
evaluate potential differences in terms of serious cardiovascular adverse events between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in December 2026]

**Action:** For adoption of advice to CHMP

### 7.5.15. Romosozumab - EVENITY (CAP) - EMEA/H/C/004465/MEA 003.2

**Applicant:** UCB Pharma S.A.

**PRAC Rapporteur:** Tiphaine Vaillant

**Scope:** First interim report for study OP0006: a European non-interventional PASS to evaluate potential differences in terms of serious infection between romosozumab and currently available therapies used in comparable patients in real-world conditions using the EU-adverse drug reactions (EU-ADR) Alliance [final study results expected in December 2024]

**Action:** For adoption of advice to CHMP

### 7.5.16. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 004.11

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Fourth interim results for study CLCZ696B2015 (PASS 3) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of Entresto/Neparvis (sacubitril/valsartan) [final study report expected in December 2022]

**Action:** For adoption of advice to CHMP

### 7.5.17. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 003.8

**Applicant:** Novartis Europharm Limited

**PRAC Rapporteur:** Anette Kirstine Stark

**Scope:** Fourth interim results for study CLCZ696B2015 (PASS 3) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of Entresto/Neparvis (sacubitril/valsartan) [final study report expected in December 2022]

**Action:** For adoption of advice to CHMP

### 7.5.18. Ustekinumab - STELARA (CAP) - EMEA/H/C/000958/MEA 045.7

**Applicant:** Janssen-Cilag International NV

**PRAC Rapporteur:** Rhea Fitzgerald
Scope: MAH’s response to MEA 045.6 [second interim report for study RRA-20745: an observational PASS to describe the safety of ustekinumab and other Crohn’s disease treatments in a cohort of patients with Crohn’s disease] as per the request for supplementary information (RSI) adopted in September 2021

**Action:** For adoption of advice to CHMP

### 7.6. Others

#### 7.6.1. Cabazitaxel - CABAZITAXEL ACCORD (CAP) - EMEA/H/C/005178/MEA 001.1

**Applicant:** Accord Healthcare S.L.U.

**PRAC Rapporteur:** Tiphaine Vaillant

**Scope:** Second six-monthly review of cases of ‘medication error’ for cabazitaxel reported during routine signal management activities

**Action:** For adoption of advice to CHMP

#### 7.6.2. Fentanyl - INSTANYL (CAP) - EMEA/H/C/000959/LEG 028.4

**Applicant:** Takeda Pharma A/S

**PRAC Rapporteur:** Tiphaine Vaillant

**Scope:** Fifth six-monthly update on the development of the child-resistant multi-dose nasal spray DoseGuard as requested in the conclusions of procedure R/0049 finalised in April 2019

**Action:** For adoption of advice to CHMP

#### 7.6.3. Insulin human - INSUMAN (CAP) - EMEA/H/C/000201/MEA 041.5

**Applicant:** Sanofi-Aventis Deutschland GmbH

**PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** MAH's request of early termination of study HUBIN-C-06380: a European observational cohort of patients with type 1 diabetes treated via intraperitoneal route with Insuman Implantable 400 IU/mL in Medtronic MiniMed implantable pump

**Action:** For adoption of advice to CHMP

#### 7.6.4. Lopinavir, ritonavir - KALETRA (CAP) - EMEA/H/C/000368/LEG 121.4

**Applicant:** AbbVie Deutschland GmbH & Co. KG

**PRAC Rapporteur:** Nathalie Gault

**Scope:** Fourth annual safety review of the PENTA - European Pregnancy and Paediatric human immunodeficiency virus (HIV) Cohort Collaboration (EPPICC) cohort study conducted in children from 14 days to 2 years of age as regards to chronic exposure to propylene glycol and ethanol and toxicity, medication errors and lack of efficacy/resistance in relation
to potentially suboptimal pharmacokinetic (PK) parameters

**Action:** For adoption of advice to CHMP

### 7.7. New Scientific Advice

None

### 7.8. Ongoing Scientific Advice

None

### 7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

### 8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

#### 8.1. Annual reassessments of the marketing authorisation

**8.1.1. Idebenone - RAXONE (CAP) - EMEA/H/C/003834/S/0029 (with RMP)**

Applicant: Santhera Pharmaceuticals (Deutschland) GmbH
PRAC Rapporteur: Amelia Cupelli
Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

**8.1.2. Metreleptin - MYALEPTA (CAP) - EMEA/H/C/004218/S/0023 (without RMP)**

Applicant: Amryt Pharmaceuticals DAC
PRAC Rapporteur: Adam Przybyłkowski
Scope: Annual reassessment of the marketing authorisation

**Action:** For adoption of advice to CHMP

#### 8.2. Conditional renewals of the marketing authorisation

**8.2.1. Andexanet alfa - ONDEXXYA (CAP) - EMEA/H/C/004108/R/0025 (without RMP)**

Applicant: Alexion Europe SAS
PRAC Rapporteur: Menno van der Elst
Scope: Conditional renewal of the marketing authorisation
8.2.2. **Bosutinib - BOSULIF (CAP) - EMEA/H/C/002373/R/0051 (without RMP)**

- **Applicant:** Pfizer Europe MA EEIG
- **PRAC Rapporteur:** Martin Huber
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

8.2.3. **Delamanid - DELTYBA (CAP) - EMEA/H/C/002552/R/0052 (without RMP)**

- **Applicant:** Otsuka Novel Products GmbH
- **PRAC Rapporteur:** Laurence de Fays
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

8.2.4. **Lorlatinib - LORVIQUA (CAP) - EMEA/H/C/004646/R/0019 (without RMP)**

- **Applicant:** Pfizer Europe MA EEIG
- **PRAC Rapporteur:** Nikica Mirošević Skvrce
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

8.2.5. **Pandemic influenza vaccine (H5N1) (live attenuated, nasal) - PANDEMIC INFLUENZA VACCINE H5N1 ASTRAZENECA (CAP) - EMEA/H/C/003963/R/0047 (without RMP)**

- **Applicant:** AstraZeneca AB
- **PRAC Rapporteur:** Sonja Hrabcik
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP

8.2.6. **Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/R/0030 (without RMP)**

- **Applicant:** Clovis Oncology Ireland Limited
- **PRAC Rapporteur:** Annika Folin
- **Scope:** Conditional renewal of the marketing authorisation
- **Action:** For adoption of advice to CHMP
8.3. **Renewals of the marketing authorisation**

8.3.1. **Beclometasone, formoterol, glycopyrronium bromide - TRIMBOW (CAP) - EMEA/H/C/004257/R/0025 (without RMP)**

Applicant: Chiesi Farmaceutici S.p.A.
PRAC Rapporteur: Jan Neuhauser
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

8.3.2. **Brodalumab - KYNTHEUM (CAP) - EMEA/H/C/003959/R/0019 (with RMP)**

Applicant: LEO Pharma A/S
PRAC Rapporteur: Eva Segovia
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

8.3.3. **Carglumic acid - UCEDANE (CAP) - EMEA/H/C/004019/R/0011 (without RMP)**

Applicant: Eurocept International B.V.
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

8.3.4. **Cariprazine - REAGILA (CAP) - EMEA/H/C/002770/R/0026 (with RMP)**

Applicant: Gedeon Richter Plc.
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

8.3.5. **Cenegermin - OXERVATE (CAP) - EMEA/H/C/004209/R/0037 (with RMP)**

Applicant: Dompe farmaceutici S.p.A.
PRAC Rapporteur: Jan Neuhauser
Scope: 5-year renewal of the marketing authorisation
**Action:** For adoption of advice to CHMP

8.3.6. **Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/R/0034 (without RMP)**

Applicant: BioMarin International Limited
<table>
<thead>
<tr>
<th>Section</th>
<th>Product Name</th>
<th>Marketing Authorisation Code</th>
<th>Applicant</th>
<th>PRAC Rapporteur</th>
<th>Scope</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.3.7</td>
<td>Dupilumab - DUPIXENT (CAP) - EMEA/H/C/004390/R/0053 (with RMP)</td>
<td></td>
<td>Sanofi-aventis groupe</td>
<td>Ulla Wändel Liminga</td>
<td>5-year renewal of the marketing authorisation</td>
<td>For adoption of advice to CHMP</td>
</tr>
<tr>
<td>8.3.8</td>
<td>Efavirenz, emtricitabine, tenofovir disoproxil - EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA (CAP) - EMEA/H/C/004250/R/0025 (without RMP)</td>
<td></td>
<td>Zentiva k.s.</td>
<td>Kimmo Jaakkola</td>
<td>5-year renewal of the marketing authorisation</td>
<td>For adoption of advice to CHMP</td>
</tr>
<tr>
<td>8.3.9</td>
<td>Etanercept - ERELZI (CAP) - EMEA/H/C/004192/R/0037 (with RMP)</td>
<td></td>
<td>Sandoz GmbH</td>
<td>Eva Segovia</td>
<td>5-year renewal of the marketing authorisation</td>
<td>For adoption of advice to CHMP</td>
</tr>
<tr>
<td>8.3.10</td>
<td>Glecaprevir, pibrentasvir - MAVIRET (CAP) - EMEA/H/C/004430/R/0048 (without RMP)</td>
<td></td>
<td>AbbVie Deutschland GmbH &amp; Co. KG</td>
<td>Ana Sofia Diniz Martins</td>
<td>5-year renewal of the marketing authorisation</td>
<td>For adoption of advice to CHMP</td>
</tr>
<tr>
<td>8.3.11</td>
<td>Insulin lispro - INSULIN LISPRO SANOFI (CAP) - EMEA/H/C/004303/R/0013 (with RMP)</td>
<td></td>
<td>Sanofi-aventis groupe</td>
<td>Annika Folin</td>
<td>5-year renewal of the marketing authorisation</td>
<td>For adoption of advice to CHMP</td>
</tr>
</tbody>
</table>
Action: For adoption of advice to CHMP

8.3.12. Osimertinib - TAGRISSO (CAP) - EMEA/H/C/004124/R/0044 (with RMP)

Applicant: AstraZeneca AB
PRAC Rapporteur: Menno van der Elst
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.13. Patiromer - VELTASSA (CAP) - EMEA/H/C/004180/R/0028 (without RMP)

Applicant: Vifor Fresenius Medical Care Renal Pharma France
PRAC Rapporteur: Kirsti Villikka
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.14. Ribociclib - KISQALI (CAP) - EMEA/H/C/004213/R/0034 (without RMP)

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Anette Kirstine Stark
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

9. **Product related pharmacovigilance inspections**

9.1. **List of planned pharmacovigilance inspections**

None

9.2. **Ongoing or concluded pharmacovigilance inspections**

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

9.3. **Others**

None
10. Other safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation

None

10.2. Timing and message content in relation to Member States’ safety announcements

None

10.3. Other requests

None

10.4. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

11. Other safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Other requests

11.2.1. Teriflunomide (pre-authorisation) - DE/H/7257/001/DC

Scope: PRAC consultation on the evaluation of an initial marketing authorisation application under the decentralised procedure for a generic teriflunomide-containing medicinal product in order to consider the need for pharmacovigilance activities, on request of Germany.

Action: For adoption of advice to Member States
12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

12.1.1. PRAC membership

Action: For information

12.1.2. Vote by proxy

None

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

Action: For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

12.7.1. PRAC work plan 2022

PRAC lead: Sabine Straus, Martin Huber

Action: For adoption
### 12.8. Planning and reporting

#### 12.8.1. Marketing authorisation applications (MAA) forecast for 2022 – planning update dated Q4 2021

**Action:** For discussion

#### 12.8.2. European Commission (EC) report on performance of pharmacovigilance tasks - third three-yearly report

**Action:** For discussion

### 12.9. Pharmacovigilance audits and inspections

#### 12.9.1. Pharmacovigilance systems and their quality systems

None

#### 12.9.2. Pharmacovigilance inspections

None

#### 12.9.3. Pharmacovigilance audits

None

### 12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

#### 12.10.1. Periodic safety update reports

None

#### 12.10.2. Granularity and Periodicity Advisory Group (GPAG)

PRAC lead: Menno van der Elst, Maia Uusküla

**Action:** For discussion

#### 12.10.3. PSURs repository

None

#### 12.10.4. Union reference date list – consultation on the draft list

**Action:** For adoption
12.11. **Signal management**


   PRAC lead: Menno van der Elst

   **Action:** For discussion

12.12. **Adverse drug reactions reporting and additional reporting**

12.12.1. **Management and reporting of adverse reactions to medicinal products**

   None

12.12.2. **Additional monitoring**

   None

12.12.3. **List of products under additional monitoring – consultation on the draft list**

   **Action:** For adoption

12.13. **EudraVigilance database**

12.13.1. **Activities related to the confirmation of full functionality**

   None


12.14.1. **Risk management systems**

   None

12.14.2. **Tools, educational materials and effectiveness measurement of risk minimisations**

   None

12.15. **Post-authorisation safety studies (PASS)**

12.15.1. **Post-authorisation Safety Studies – imposed PASS**

   None
12.15.2. Post-authorisation Safety Studies – non-imposed PASS

None

12.16. Community procedures

12.16.1. Referral procedures for safety reasons

None

12.17. Renewals, conditional renewals, annual reassessments

None

12.18. Risk communication and transparency

12.18.1. Public participation in pharmacovigilance

None

12.18.2. Safety communication

None

12.19. Continuous pharmacovigilance

12.19.1. Incident management

None

12.20. Impact of pharmacovigilance activities

None

12.21. Others

12.21.1. EMA guidance on companion diagnostics (CDx) – consultation CHMP/CAT assessment report (AR) CDx template - update

Action: For discussion


PRAC lead: Amelia Cupelli, Maria del Pilar Rayon, Liana Gross-Martirosyan, Martin Huber,
Eva Segovia, Sabine Straus, Menno van der Elst, Ulla Wändel Liminga

**Action**: For discussion

## 13. Any other business
14. **Explanatory notes**

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

**EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures**  
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:  

**Signals assessment and prioritisation**  
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks. The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event. The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

**Risk Management Plans (RMPs)**  
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

**Assessment of Periodic Safety Update Reports (PSURs)**  
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

**Post-authorisation Safety Studies (PASS)**  
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

**Product related pharmacovigilance inspections**  
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations. More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)